

Pharmaceutical Combination

Comprising a T-type calcium channel blocker

- 5 The present invention relates to a pharmaceutical combination comprising a first active ingredient which is N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof and a second active ingredient which has an anti-epileptic effect or a pharmaceutically acceptable salt thereof.
- 10 Epilepsy is a brain disorder characterized by an enduring predisposition to generate seizures and by the neurobiological, cognitive, psychological, and social consequences of this condition (Berg AT et al. (2011) New concepts in classification of the epilepsies: entering the 21st century. *Epilepsia* 52:1058–1062; Berg AT et al. (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE
- 15 Commission on Classification and Terminology, 2005–2009. *Epilepsia* 51:676–685). Epileptic patients experience recurrent spontaneous seizures, which may present various phenotypes ranging from mild brief lapses of attention or muscle jerks up to severe and prolonged convulsions. Seizures are transient events due to abnormal, excessive, or synchronous neuronal activity in the brain. They are classified either as focal seizures
- 20 when they remain restricted to networks in one hemisphere or as generalized (absence, myoclonic, tonic clonic, tonic and atonic) seizures when they rapidly engage bilaterally distributed networks.
- Anti-epileptic drugs (AEDs) aim at reducing seizure activity. Currently approved AEDs act mainly on multiple ion channels (Ca^{2+} , Na^{+} , K^{+} or Cl^{-}), synaptic systems and amino-acid
- 25 receptors, on neurons and glial cells. AEDs are currently prescribed based primarily on consideration of individual's seizure type(s), comorbidities and co-medications (Perucca E et al. (2011) The pharmacological treatment of epilepsy in adults. *Lancet Neurol* 10:446–456; Franco V et al. (2016) Challenges in the clinical development of new antiepileptic drugs. *Pharmacol Res* 103:95–104) but age, sex, childbearing potential are also
- 30 considered. Even today there are no reliable tools to predict clinical responses in the individual patient.
- Newly diagnosed patients are given one of the first line treatment (such as Carbamazepine, Ethosuximide, Lamotrigine, Levetiracetam, Oxcarbazepine, Phenytoin, Topiramate, Valproic acid or salts thereof) chosen based on individual patient characteristics. Treatment
- 35 usually starts with low dose which is up-titrated during a period which varies for each drug.

Maintenance dose is typically adapted for each patient and should be the lowest dose that provides seizure freedom. This initial selected maintenance dose can be increased when seizures recur (Perucca E et al. (2011) The pharmacological treatment of epilepsy in adults. *Lancet Neurol* 10:446-456). Approximately 50% of adult epileptic patients will stay on monotherapy with the initial AED prescribed, meaning that they achieved seizure freedom without intolerable side effects. For the remaining 50%, treatment needs adaptation and a common option is to combine AEDs. Pharmacoresistant epilepsies represent about 30% of the epileptic population and have been defined by the International League Against Epilepsy (ILAE) as the failure to achieve seizure freedom despite adequate trials of at least two appropriately chosen and tolerated AED schedules, given alone or in combination (Kwan P et al. (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia* 51:1069-1077). Most patients with refractory epilepsy take 2, 3 or 4 different AEDs. Since more than 25 AEDs are currently available in the market, there are, in theory, a huge number of possible combinations. This explains the recommendation for a rational polytherapy, i.e. combination of AEDs having different pharmacological properties (Brodie MJ et al. (2011) Antiepileptic drug therapy: does mechanism of action matter? *Epilepsy Behav* 21:331-341; Brodie MJ et al. (2011) Combining antiepileptic drugs - rational polytherapy? *Seizure* 20:369-375; Brodie MJ (2016) Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide. *Curr Neurol Neurosci Rep* 16:82). Indeed, most successful combination therapy is observed with drugs having different mechanisms of action (Stephen LJ et al. (2012) Antiepileptic drug combinations - have newer agents altered clinical outcomes? *Epilepsy Res* 98:194-198; Brodie MJ (2016) Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide. *Curr Neurol Neurosci Rep* 16:82). However, retrospective analysis of an extensive database of AED therapy in refractory patients showed that combination of more than 2 drugs is in most cases not significantly beneficial to patients (Poolos NP et al. (2012) Comparative efficacy of combination drug therapy in refractory epilepsy. *Neurology* 78:62-68).

Calcium (Ca^{2+}) is an important signal transduction element in neurons and its entry into the cell is tightly regulated by two major classes of voltage gated calcium channels: the high-voltage activated (HVA; L-, N-, P/Q- and R-types) and the low-voltage activated (LVA; T-type) calcium channels (Catterall WA et al. (2005) International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. *Pharmacol Rev* 57:411-425).

Three T-type calcium channel subtypes with different electrophysiological properties have been described: $\text{Ca}_v3.1$, $\text{Ca}_v3.2$ and $\text{Ca}_v3.3$ (Lee JH et al. (1999) Cloning and expression of

- a novel member of the low voltage-activated T-type calcium channel family. *J Neurosci* 19:1912-1921; Perez-Reyes E (2003) Molecular physiology of low-voltage-activated t-type calcium channels. *Physiol Rev* 83:117-161). T-type calcium channels are widely expressed in the brain (Talley EM et al. (1999) Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. *J Neurosci* 19:1895-1911), where they play an important role in the control of rhythmic neuronal burst firing and resultant thalamocortical oscillations (Cheong E et al. (2014) T-type Ca^{2+} channels in absence epilepsy. *Pflugers Arch* 466:719-734; Lambert RC et al. (2014) The many faces of T-type calcium channels. *Pflugers Arch* 466:415-423).
- 10 Abnormal T-type calcium channel mediated oscillations can be observed during idiopathic generalized epilepsies (IGE) seizures, in particular absence seizures, in both humans and animals (Khosravani H et al. (2006) Voltage-gated calcium channels and idiopathic generalized epilepsies. *Physiol Rev* 86:941-966; Zamponi GW et al. (2010) Role of voltage-gated calcium channels in epilepsy. *Pflugers Arch* 460:395-403; Cheong E et al. (2014) T-type Ca^{2+} channels in absence epilepsy. *Pflugers Arch* 466:719-734).
- 15 In line with these observations, mutations were identified in the gene expressing the $\text{Ca}_v3.2$ subtype in patients with childhood absence epilepsy and other forms of IGE (Khosravani H et al. (2006) Voltage-gated calcium channels and idiopathic generalized epilepsies. *Physiol Rev* 86:941-966; Heron SE et al. (2007) Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants. *Ann Neurol* 62:560-568; Zamponi GW et al. (2010) Role of voltage-gated calcium channels in epilepsy. *Pflugers Arch* 460:395-403; Eckle VS et al. (2014) Mechanisms by which a CACNA1H mutation in epilepsy patients increases seizure susceptibility. *J Physiol* 592:795-809). Several of these mutations increase the intrinsic activity of the channels, whereas others increase the intracellular trafficking of the channels to the plasma membrane; most mutations enhance calcium currents. A direct consequence of this is increased excitability in neurons that exhibit enhanced bursting activity, thereby contributing to the generation of epileptiform discharges. Several rodent models confirm the importance of the $\text{Ca}_v3.2$ channel subtype. In genetic rat models of spontaneous absence-like epilepsy (GAERS, Genetic Absence Epilepsy in Rats from Strasbourg; WAG/Rij), a gain-of-function mutation of the $\text{Ca}_v3.2$ gene has been reported (Powell KL et al. (2009) A $\text{Ca}_v3.2$ T-type calcium channel point mutation has splice-variant-specific effects on function and segregates with seizure expression in a polygenic rat model of absence epilepsy. *J Neurosci* 29:371-380), as well as elevated levels of $\text{Ca}_v3.2$ mRNA, and increased T-type calcium currents (Tsakiridou E et al. (1995) Selective increase in T-type calcium conductance of reticular thalamic neurons in a rat model of absence epilepsy. *J Neurosci* 15:3110-3117; Talley EM et al. (2000) Low-voltage-
- 20
25
30
35

activated calcium channel subunit expression in a genetic model of absence epilepsy in the rat. *Brain Res Mol Brain Res* 75:159-165; Broicher T et al. (2008) Correlation of T-channel coding gene expression, IT, and the low threshold Ca^{2+} spike in the thalamus of a rat model of absence epilepsy. *Mol Cell Neurosci* 39:384-399; Powell KL et al. (2009) A $\text{Ca}_v3.2$ T-type calcium channel point mutation has splice-variant-specific effects on function and segregates with seizure expression in a polygenic rat model of absence epilepsy. *J Neurosci* 29:371-380). Acquired channelopathies involving long-term alterations in thalamic $\text{Ca}_v3.2$ channels have also been described for a mouse model of temporal lobe epilepsy (Graef JD et al. (2009) An acquired channelopathy involving thalamic T-type Ca^{2+} channels after status epilepticus. *J Neurosci* 29:4430-4441).

Several lines of evidence link mutations in the $\text{Ca}_v3.1$ subtype with epilepsy in humans and in rodent animal models. Genetic variants have been detected in patients with juvenile myoclonic epilepsy, another form of IGE (Lory P et al. (2010) Calcium channelopathies in inherited neurological disorders: Relevance to drug screening for acquired channel disorders. *IDrugs* 13:467-471). Overexpression of $\text{Ca}_v3.1$ channels in mice leads to frequent bilateral cortical seizures (Ernst WL et al. (2009) Genetic enhancement of thalamocortical network activity by elevating $\alpha 1\text{g}$ -mediated low-voltage-activated calcium current induces pure absence epilepsy. *J Neurosci* 29:1615-1625) and $\text{Ca}_v3.1$ knockout mice are protected from absence seizures (Kim D et al. (2001) Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking $\alpha 1\text{G}$ T-type Ca^{2+} channels. *Neuron* 31:35-45; Song I et al. (2004) Role of the $\alpha 1\text{G}$ T-type calcium channel in spontaneous absence seizures in mutant mice. *J Neurosci* 24:5249-5257).

It was surprisingly found that N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide showed a synergistic effect in a mouse model of generalized tonic-clonic seizures when administered together with existing AEDs.

Summary

In one aspect, there is provided a pharmaceutical combination comprising a first active ingredient which is N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof and a second active ingredient which has an anti-epileptic effect, or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a pharmaceutical combination as described herein for use as a medicament.

In yet another aspect, there is provided a pharmaceutical composition containing, as active principle, N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient, wherein the pharmaceutical composition is to be administered in combination with a second pharmaceutical composition containing, as active principle, 5*H*-dibenzo[*b,f*]azepine-5-carboxamide, (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione, 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide, 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide, 2-propylpentanoic acid, *N*-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide, (*2S*)-2-[(*4R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide, 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione, 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one, (*S*)-10-acetoxy-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-5-carboxamide, (3-carbamoyloxy-2-phenylpropyl) carbamate, 1-(aminomethyl)cyclohexaneacetic acid, (*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide, 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'(1*H*)-one, 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione, 5,5-diphenylimidazolidine-2,4-dione, 2-(2-oxopyrrolidin-1-yl)acetamide, (*3S*)-3-(aminomethyl)-5-methylhexanoic acid, 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione, ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate, 1-(2,6-difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide, (*RS*)-(E)-4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol, (*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid, 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate, (*RS*)-4-amino-5-enoic acid, or benzo[*d*]isoxazol-3-ylmethanesulfonamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

In another aspect, there is provided a pharmaceutical composition containing, as active principle, 5*H*-dibenzo[*b,f*]azepine-5-carboxamide, (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione, 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide, 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide, 2-propylpentanoic acid, *N*-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide, (*2S*)-2-[(*4R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide, 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione, 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one, (*S*)-10-acetoxy-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-5-carboxamide, (3-carbamoyloxy-2-phenylpropyl) carbamate, 1-(aminomethyl)cyclohexaneacetic acid, (*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide, 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'(1*H*)-one, 5-ethyl-5-

phenyl-1,3-diazinane-2,4,6-trione, 5,5-diphenylimidazolidine-2,4-dione, 2-(2-oxopyrrolidin-1-yl)acetamide, (3S)-3-(aminomethyl)-5-methylhexanoic acid, 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione, ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate, 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, (RS)-(E)-4,4-dimethyl-1-
 5 [3,4(methylenedioxy)-phenyl]-1-penten-3-ol, (3R)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid, 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate, (RS)-4-aminohex-5-enoic acid, or benzo[d]isoxazol-3-ylmethanesulfonamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient, wherein the pharmaceutical composition is to be administered in combination with a
 10 second pharmaceutical composition containing, as active principle, N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

In another aspect, there is provided a kit of parts comprising a first pharmaceutical
 15 composition containing, as active principle, N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient; and a second pharmaceutical composition containing, as active principle, 5H-dibenzo[b,f]azepine-5-carboxamide, (RS)-3-ethyl-3-methyl-pyrrolidine-2,5-dione, 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, (S)-
 20 2-(2-oxopyrrolidin-1-yl)butanamide, 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide, 2-propylpentanoic acid, N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide, (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide, 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione, 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one, (S)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide, (3-carbamoyloxy-2-
 25 phenylpropyl) carbamate, 1-(aminomethyl)cyclohexaneacetic acid, (R)-2-acetamido-N-benzyl-3-methoxypropanamide, 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'(1'H)-one, 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione, 5,5-diphenylimidazolidine-2,4-dione, 2-(2-oxopyrrolidin-1-yl)acetamide, (3S)-3-(aminomethyl)-5-methylhexanoic acid, 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione, ethyl (2-amino-4-((4-
 30 fluorobenzyl)amino)phenyl)carbamate, 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, (RS)-(E)-4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol, (3R)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid, 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate, (RS)-4-aminohex-5-enoic acid, or benzo[d]isoxazol-3-ylmethanesulfonamide, or a pharmaceutically acceptable salt thereof,
 35 and at least one therapeutically inert excipient.

Description of the invention:

- 1) In a first embodiment the present invention relates to a pharmaceutical combination comprising a first active ingredient which is N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide (hereinafter also referred to as
- 5 "COMPOUND 1") or a pharmaceutically acceptable salt thereof and a second active ingredient which has an anti-epileptic effect, or a pharmaceutically acceptable salt thereof.

COMPOUND 1 is a selective and orally available triple T-type calcium channel blocker, i.e. COMPOUND 1 blocks the three T-type calcium channel subtypes $Ca_v3.1$, $Ca_v3.2$ and $Ca_v3.3$. COMPOUND 1 has been described to be useful in the prevention/prophylaxis

and/or treatment of diseases or disorders where calcium T channels are involved and especially in the treatment of epilepsy (WO 2015/186056). COMPOUND 1 may be prepared according to the procedure as disclosed in WO 2015/186056.

It is to be understood that the present invention encompasses COMPOUND 1 in any form including amorphous as well as crystalline forms of COMPOUND 1. It is further to be understood that crystalline forms of COMPOUND 1 encompasses all types of crystalline forms of COMPOUND 1 including polymorphs of the mere molecule, solvates and hydrates, molecular salts and co-crystals (when the same molecule can be co-crystallized with different co-crystal formers) provided they are suitable for pharmaceutical administration.

2) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine), (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), *N*-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide (Acetazolamide), (2*S*)-2-[(4*R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide (Brivaracetam), 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam), 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), (*S*)-10-acetoxy-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Eslicarbazepine acetate), (3-carbamoyloxy-2-phenylpropyl) carbamate (Felbamate), 1-(aminomethyl)cyclohexanecarboxylic acid (Gabapentin), (*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide (Lacosamide), 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'-(1'*H*)-one (Perampanel), 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), 2-(2-oxopyrrolidin-1-yl)acetamide (Piracetam), (3*S*)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin), 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone), ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate (Retigabine), 1-(2,6-difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide (Rufinamide), (*RS*)-(*E*)-4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol (Stiripentol), (3*R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (Tiagabine), 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate), (*RS*)-4-aminohex-5-enoic acid (Vigabatrin), and benzo[*d*]isoxazol-3-ylmethanesulfonamide (Zonisamide); or a pharmaceutically acceptable salt of any of the aforementioned.

Carbamazepine (5*H*-dibenzo[*b,f*]azepine-5-carboxamide) is described to be effective for the treatment of focal seizures and tonic clonic seizures. Pharmaceutical compositions

comprising Carbamazepine are available in different dosage forms such as tablets, chewtabs, suspensions and suppositories; tablets are also available in a prolonged release form. The average total dose administered per day for adults is 600 to 2000mg and is typically given in 2 to 4 doses. Carbamazepine can be prepared according to procedures
5 known in the art, for example as described in US 2,948,718.

(*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide) is described to be effective for the treatment of absence seizures. Pharmaceutical compositions comprising Ethosuximide are available in different dosage forms such as capsules or syrups. The average total dose administered per day for adults is 750 to 1500mg and is typically given in 2 or 3 doses.
10 Ethosuximide can be prepared according to procedures known in the art, for example as described in Sircar SSG (1927), J. Chem. Soc. 1252-1256.

6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine) is described to be effective for the treatment of focal seizures and tonic clonic seizures. Pharmaceutical compositions comprising Lamotrigine are available in different dosage forms such as tablets and dispersible tablets. The average total dose administered per day for adults is 100 to 400mg
15 and is typically given in 1 or 2 doses. Lamotrigine can be prepared according to procedures known in the art, for example as described in EP 0021121.

(*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam) is described to be effective for the treatment of focal seizures, tonic clonic seizures and myoclonic seizures. Pharmaceutical
20 compositions comprising Levetiracetam are available in different dosage forms such as tablets and oral solutions. The average total dose administered per day for adults is 1000 to 3000mg and is typically given in 2 doses. Levetiracetam can be prepared according to procedures known in the art, for example as described in US 4,943,639.

10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine) is described to
25 be effective for the treatment of focal seizures and secondarily generalized seizures. Pharmaceutical compositions comprising Oxcarbazepine are available in different dosage forms such as tablets and oral suspensions. The average total dose administered per day for adults is 1200 to 2400mg and is typically given in 2 or 3 doses. Oxcarbazepine can be prepared according to procedures known in the art, for example as described in US
30 3,642,775.

2-propylpentanoic acid (Valproic acid) is described to be effective for the treatment of focal seizures, tonic clonic seizures and absence seizures. It is understood that sodium valproate is a preferred pharmaceutically acceptable salt of valproic acid. It is further understood that any reference to "valproic acid or a pharmaceutically acceptable salt
35 thereof" refers to valproic acid, to a pharmaceutically acceptable salt of valproic acid

(especially sodium valproate) and to a mixture of valproic acid and a pharmaceutically acceptable salt of valproic acid such as especially a mixture of valproic acid and sodium valproate (notably a mixture in a 1:1 molar ratio: divalproex sodium, Valproate semisodium). Pharmaceutical compositions comprising valproic acid and/or sodium valproate are available in different dosage forms such as tablets, crushable tablets, liquids and syrups; tablets and granules are also available in a prolonged release form. The average total dose administered per day for adults is 400 to 2000mg and is typically given in 1 or 2 doses. Valproic acid and sodium valproate can be prepared according to procedures known in the art, for example as described in EP 0835859.

10 *N*-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide (Acetazolamide) is described to be effective for the treatment of focal seizures, tonic clonic seizures and absence seizures. Pharmaceutical compositions comprising Acetazolamide are available in different dosage forms such as tablets and powder; capsules are available in a prolonged release form. The average total dose administered per day for adults is 250 to 1000mg and is typically given
15 in 2 or 3 doses. Acetazolamide can be prepared according to procedures known in the art, for example as described in US 2,554,816.

(2*S*)-2-[(4*R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide (Brivaracetam) is described to be effective for the treatment of focal seizures. Pharmaceutical compositions comprising Brivaracetam are available in different dosage forms such as tablets and solutions. The
20 average total dose administered per day for adults is 50 to 200mg and is typically given in 2 doses. Brivaracetam can be prepared according to procedures known in the art, for example as described in Kenda BM et al. (2004), J. Med. Chem., 47, 530-549.

7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam) is described to be effective for the treatment of focal seizures and tonic clonic seizures. Pharmaceutical
25 compositions comprising Clobazam are available in different dosage forms such as tablets and suspensions. The average total dose administered per day for adults is 20 to 60mg and is typically given in 1 or 2 doses. Clobazam can be prepared according to procedures known in the art, for example as described in US 3,984,398.

5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam) is described
30 to be effective for the treatment of focal seizures, tonic clonic seizures, myoclonic seizures and absence seizures. Pharmaceutical compositions comprising Clonazepam are available in different dosage forms such as tablets and solutions. The average total dose administered per day for adults is 1 to 4mg and is typically given in 2 doses. Clonazepam can be prepared according to procedures known in the art, for example as described in US
35 3,121,076.

(S)-10-acetoxy-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Eslicarbazepine acetate) is described to be effective for the treatment of focal seizures. Pharmaceutical compositions comprising Eslicarbazepine acetate are available as tablets. The average total dose administered per day for adults is 800 to 1200mg and is typically given in 1 dose.

5 Eslicarbazepine acetate can be prepared according to procedures known in the art, for example as described in WO 2007/012793.

(3-carbamoyloxy-2-phenylpropyl) carbamate (Felbamate) is described to be effective for the treatment of focal seizures and tonic clonic seizures. Pharmaceutical compositions comprising Felbamate are available in different dosage forms such as tablets and
10 suspensions. The average total dose administered per day for adults is 1200 to 3600mg and is typically given in 3 or 4 doses. Felbamate can be prepared according to procedures known in the art, for example as described in US 2,884,444.

1-(aminomethyl)cyclohexanecarboxylic acid (Gabapentin) is described to be effective for the treatment of focal seizures. Pharmaceutical compositions comprising Gabapentin are
15 available in different dosage forms such as tablets, capsules and solutions. The average total dose administered per day for adults is 1800 to 3600mg and is typically given in 3 doses. Gabapentin can be prepared according to procedures known in the art, for example as described in US 4,024,175.

(*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide (Lacosamide) is described to be effective
20 for the treatment of focal seizures. Pharmaceutical compositions comprising Lacosamide are available in different dosage forms such as tablets, solutions and syrups. The average total dose administered per day for adults is 200 to 400mg and is typically given in 2 doses. Lacosamide can be prepared according to procedures known in the art, for example as described in Choi D et al. (1996), J. Med. Chem., 39, 1907-1916.

25 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'-(1*H*)-one (Perampanel) is described to be effective for the treatment of focal seizures and tonic clonic seizures. Pharmaceutical compositions comprising Perampanel are available as tablets. The average total dose administered per day for adults is 4 to 12mg and is typically given in 1 dose. Perampanel can be prepared according to procedures known in the art, for example as described in Hibi
30 S et al. (2012), J. Med. Chem., 55(23), 10584-10600.

5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital) is described to be effective for the treatment of focal seizures and tonic clonic seizures. Pharmaceutical compositions comprising Phenobarbital are available in different dosage forms such as tablets and solutions. The average total dose administered per day for adults is 30 to 180mg and is

typically given in 2 doses. Phenobarbital can be prepared according to procedures known in the art, for example as described in US 1,025,872.

5,5-diphenylimidazolidine-2,4-dione (Phenytoin) is described to be effective for the treatment of focal seizures and tonic clonic seizures. It is understood that Phenytoin sodium is a preferred pharmaceutically acceptable salt of Phenytoin. It is further understood that any reference to "Phenytoin or a pharmaceutically acceptable salt thereof" refers to Phenytoin and to a pharmaceutically acceptable salt of Phenytoin (especially Phenytoin sodium). Pharmaceutical compositions comprising Phenytoin or Phenytoin sodium are available in different dosage forms such as tablets, chewable tablets, capsules, solutions and suspensions. The average total dose administered per day for adults is 150 to 500mg and is typically given in 1 or 2 doses. Phenytoin can be prepared according to procedures known in the art, for example as described in US 2,409,754.

2-(2-oxopyrrolidin-1-yl)acetamide (Piracetam) is described to be effective for the treatment of myoclonic seizures. Pharmaceutical compositions comprising Piracetam are available in different dosage forms such as tablets and solutions. The average total dose administered per day for adults is 7.2 to 24mg and is typically given in 2 or 3 doses. Piracetam can be prepared according to procedures known in the art, for example as described in US 3,459,738.

(3S)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin) is described to be effective for the treatment of focal seizures. Pharmaceutical compositions comprising Pregabalin are available in different dosage forms such as capsules and solutions. The average total dose administered per day for adults is 300 to 600mg and is typically given in 2 doses. Pregabalin can be prepared according to procedures known in the art, for example as described in Hoekstra et al., Org. Process Res. Dev. 1997, 1, 26-38.

5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone) is described to be effective for the treatment of focal seizures and tonic clonic seizures. Pharmaceutical compositions comprising Primidone are available as tablets. The average total dose administered per day for adults is 500 to 1500mg and is typically given in 2 to 4 doses. Primidone can be prepared according to procedures known in the art, for example as described in GB 1597796.

ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate (Retigabine) is described to be effective for the treatment of focal seizures. Pharmaceutical compositions comprising Retigabine are available as tablets. The average total dose administered per day for adults is 900 to 1200mg and is typically given in 3 doses. Retigabine can be prepared according

to procedures known in the art, for example as described in US 5384330 or in WO 2012/098075.

1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide (Rufinamide) is described to be effective for the treatment of seizures associated with Lennox-Gastaut syndrome. Pharmaceutical compositions comprising Rufinamide are available in different dosage forms such as tablets and suspensions. The average total dose administered per day for adults is 200 to 3600mg and is typically given in 2 doses. Rufinamide can be prepared according to procedures known in the art, for example as described in US 4789680.

(*RS*)-(*E*)-4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol (Stiripentol) is described to be effective for the treatment of tonic clonic seizures in severe myoclonic epilepsy in infancy (SMEI or Dravet syndrome). Pharmaceutical compositions comprising Stiripentol are available in different dosage forms such as capsules and powder. The average total dose administered per day for adults is up to 50mg/kg and is typically given in 2 or 3 doses. Stiripentol can be prepared according to procedures known in the art, for example as described in DE 2308494.

(*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (Tiagabine) is described to be effective for the treatment of focal seizures. It is understood that (*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid hydrochloride is a preferred pharmaceutically acceptable salt of Tiagabine. It is further understood that any reference to "(*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid or a pharmaceutically acceptable salt thereof" refers to (*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid and to a pharmaceutically acceptable salt of (*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (especially (*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid hydrochloride). Pharmaceutical compositions comprising (*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid and/or (*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid hydrochloride are available as tablets. The average total dose administered per day for adults is 30 to 45mg and is typically given in 1 to 3 doses. (*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid and (*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid hydrochloride can be prepared according to procedures known in the art, for example as described in Andersen et al., J. Med. Chem. 1993, 36(12), 1716.

2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate) is described to be effective for the treatment of focal seizures and tonic clonic seizures. Pharmaceutical compositions comprising Topiramate are available in different dosage forms such as

tablets and capsules. The average total dose administered per day for adults is 200 to 400mg and is typically given in 2 doses. Topiramate can be prepared according to procedures known in the art, for example as described in Maryanoff et al., J. Med. Chem. 1987, 30(5), 880.

- 5 (RS)-4-aminohex-5-enoic acid (Vigabatrin) is described to be effective for the treatment of focal seizures. Pharmaceutical compositions comprising Vigabatrin are available in different dosage forms such as tablets and granules. The average total dose administered per day for adults is 1000 to 4000mg and is typically given in 1 or 2 doses. Vigabatrin can be prepared according to procedures known in the art, for example as described in EP
10 0427197.

benzo[d]isoxazol-3-ylmethanesulfonamide (Zonisamide) is described to be effective for the treatment of focal seizures. Pharmaceutical compositions comprising Zonisamide are available as capsules. The average total dose administered per day for adults is 300 to 500mg and is typically given in 1 or 2 doses. Zonisamide can be prepared according to
15 procedures known in the art, for example as described in Uno et al., J. Med. Chem. 1979, 22(2), 180.

- 3) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of 5H-dibenzo[b,f]azepine-5-carboxamide (Carbamazepine), (RS)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (S)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), and 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate (Topiramate); or a pharmaceutically
20 acceptable salt of any of the aforementioned.

- 4) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of 5H-dibenzo[b,f]azepine-5-carboxamide (Carbamazepine), (RS)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (S)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide (Oxcarbazepine), and 2-propylpentanoic acid (Valproic acid); or a pharmaceutically acceptable salt of any of the
30 aforementioned.

- 5) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group
35

consisting of 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine), (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam), 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone), 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate), and benzo[*d*]isoxazol-3-ylmethanesulfonamide (Zonisamide); or a pharmaceutically acceptable salt of any of the aforementioned.

6) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), 2-propylpentanoic acid (Valproic acid), and 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate); or a pharmaceutically acceptable salt of any of the aforementioned.

7) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), and 2-propylpentanoic acid (Valproic acid); or a pharmaceutically acceptable salt of any of the aforementioned.

8) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam), 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone), 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate), and benzo[*d*]isoxazol-3-ylmethanesulfonamide (Zonisamide); or a pharmaceutically acceptable salt of any of the aforementioned.

9) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), 2-

propylpentanoic acid (Valproic acid), and 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate); or a pharmaceutically acceptable salt of any of the aforementioned.

10) A further embodiment of the invention relates to a pharmaceutical combination
 5 according to embodiment 1), wherein the second active ingredient is selected from the group consisting of (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 2-propylpentanoic acid (Valproic acid), and 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam); or a
 10 pharmaceutically acceptable salt of any of the aforementioned.

11) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), and 2-propylpentanoic acid (Valproic acid); or a pharmaceutically acceptable salt of any of the
 15 aforementioned.

12) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5*H*-
 20 dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), (2*S*)-2-[(4*R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide (Brivaracetam), 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam), (*S*)-10-acetoxy-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Eslicarbazepine acetate), 1-(aminomethyl)cyclohexanecarboxylic acid (Gabapentin), (*R*)-2-acetamido-*N*-benzyl-3-
 25 methoxypropanamide (Lacosamide), 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'-(1*H*)-one (Perampanel), 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), (3*S*)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin), 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone), ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate (Retigabine), 1-(2,6-difluorobenzyl)-1*H*-1,2,3-
 30 triazole-4-carboxamide (Rufinamide), (3*R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (Tiagabine), 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate), (*RS*)-4-aminohex-5-enoic acid (Vigabatrin), and benzo[*d*]isoxazol-3-ylmethanesulfonamide (Zonisamide); or a pharmaceutically acceptable salt of any of the aforementioned.

13) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine), (S)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), (S)-10-acetoxy-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Eslicarbazepine acetate), 1-(aminomethyl)cyclohexanecarboxylic acid (Gabapentin), (*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide (Lacosamide), 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), (3*S*)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin), 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone), 1-(2,6-difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide (Rufinamide), (3*R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (Tiagabine), 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate), and benzo[*d*]isoxazol-3-ylmethanesulfonamide (Zonisamide); or a pharmaceutically acceptable salt of any of the
15
aforementioned.

14) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine), (S)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), and 2-propylpentanoic acid (Valproic acid); or a pharmaceutically acceptable salt of any of the aforementioned.
20

15) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), and 5,5-diphenylimidazolidine-2,4-dione (Phenytoin); or a pharmaceutically acceptable salt of any of the aforementioned.
25

16) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), 2-propylpentanoic acid (Valproic acid), 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), 2-(2-oxopyrrolidin-1-yl)acetamide (Piracetam), and 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate); or a pharmaceutically acceptable salt of any of the aforementioned.
30

17) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is selected from the group consisting of (S)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), and 2-propylpentanoic acid (Valproic acid); or a pharmaceutically acceptable salt of any of the
5 aforementioned.

18) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is 5H-dibenzo[b,f]azepine-5-carboxamide (Carbamazepine) or a pharmaceutically acceptable salt thereof.

10 19) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is (RS)-3-ethyl-3-methylpyrrolidine-2,5-dione (Ethosuximide) or a pharmaceutically acceptable salt thereof.

20) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine) or a pharmaceutically acceptable
15 salt thereof.

21) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is (S)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam) or a pharmaceutically acceptable salt thereof.

20 22) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide (Oxcarbazepine) or a pharmaceutically acceptable salt thereof.

23) A further embodiment of the invention relates to a pharmaceutical combination
25 according to embodiment 1), wherein the second active ingredient is 2-propylpentanoic acid (Valproic acid) or a pharmaceutically acceptable salt thereof.

24) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide (Acetazolamide) or a pharmaceutically acceptable salt thereof.

30 25) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide (Brivaracetam) or a pharmaceutically acceptable salt thereof.

- 26) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam) or a pharmaceutically acceptable salt thereof.
- 5 27) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam) or a pharmaceutically acceptable salt thereof.
- 28) A further embodiment of the invention relates to a pharmaceutical combination
10 according to embodiment 1), wherein the second active ingredient is (S)-10-acetoxy-10,11-dihydro-5*H*-dibenz[b,f]azepine-5-carboxamide (Eslicarbazepine acetate) or a pharmaceutically acceptable salt thereof.
- 29) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is (3-carbamoyloxy-2-
15 phenylpropyl) carbamate (Felbamate) or a pharmaceutically acceptable salt thereof.
- 30) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is 1-(aminomethyl)cyclohexanecarboxylic acid (Gabapentin) or a pharmaceutically acceptable salt thereof.
- 20 31) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is (*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide (Lacosamide) or a pharmaceutically acceptable salt thereof.
- 32) A further embodiment of the invention relates to a pharmaceutical combination
25 according to embodiment 1), wherein the second active ingredient is 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'-(1'*H*)-one (Perampanel) or a pharmaceutically acceptable salt thereof.
- 33) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital) or a pharmaceutically acceptable salt thereof.
30
- 34) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is 5,5-diphenylimidazolidine-2,4-dione (Phenytoin) or a pharmaceutically acceptable salt thereof.

- 35) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is 2-(2-oxopyrrolidin-1-yl)acetamide (Piracetam) or a pharmaceutically acceptable salt thereof.
- 36) A further embodiment of the invention relates to a pharmaceutical combination
5 according to embodiment 1), wherein the second active ingredient is (3S)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin) or a pharmaceutically acceptable salt thereof.
- 37) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone) or a pharmaceutically acceptable salt thereof.
- 10 38) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate (Retigabine) or a pharmaceutically acceptable salt thereof.
- 39) A further embodiment of the invention relates to a pharmaceutical combination
15 according to embodiment 1), wherein the second active ingredient is 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide (Rufinamide) or a pharmaceutically acceptable salt thereof.
- 40) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is (RS)-(E)-4,4-dimethyl-
20 1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol (Stiripentol) or a pharmaceutically acceptable salt thereof.
- 41) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is (3R)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (Tiagabine) or a
25 pharmaceutically acceptable salt thereof.
- 42) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate) or a pharmaceutically acceptable salt thereof.
- 30 43) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is (RS)-4-aminohex-5-enoic acid (Vigabatrin) or a pharmaceutically acceptable salt thereof.

44) A further embodiment of the invention relates to a pharmaceutical combination according to embodiment 1), wherein the second active ingredient is benzo[d]isoxazol-3-ylmethanesulfonamide (Zonisamide) or a pharmaceutically acceptable salt thereof.

45) A further embodiment of the invention relates to a pharmaceutical combination
5 according to any one of embodiments 1) to 44), wherein the first and the second active ingredient are comprised in a single pharmaceutical composition.

In a special case of embodiment 45) where one active ingredient is administered more frequently than the other active ingredient, only one or several (up to the number of administrations for the less frequently administered active ingredient) of the pharmaceutical
10 compositions needed per day will contain both, the first and the second active ingredient. For example, where one of the two active ingredients is administered once daily and the other active ingredient is administered twice daily, only one of the two pharmaceutical compositions needed per day will contain both, the first and the second active ingredient whereas the other will only contain the active ingredient that is administered twice daily.

15 Moreover, in case of a pharmaceutical combination according to embodiment 45) where the first and/or the second active ingredient is administered according to a dose up-titration regimen the pharmaceutical compositions needed for the dose up-titration will contain the amounts of active ingredient required for the different steps of the dose up-titration regimen.

20 46) A further embodiment of the invention relates to a pharmaceutical combination according to any one of embodiments 1) to 44), wherein the first and the second active ingredient are comprised in separated pharmaceutical compositions.

In case the first and the second active ingredient are comprised in separated pharmaceutical compositions, they can be administered simultaneously, sequentially or
25 separately; preferably the separated pharmaceutical compositions are administered simultaneously or sequentially, especially sequentially. In case the first active ingredient is for example administered once daily and the second active ingredient twice daily, then the separated pharmaceutical compositions are preferably administered one time per day simultaneously or sequentially, especially sequentially. If administered sequentially or
30 separately, the separated pharmaceutical compositions may be administered in one or the other order. The number of administrations per day may be the same or different for the separated pharmaceutical compositions. For instance, one pharmaceutical composition may be administered twice daily and the other pharmaceutical composition may be administered once or twice daily. Preferably the pharmaceutical composition comprising
35 COMPOUND 1 is administered once daily and the pharmaceutical composition comprising

the second active ingredient is administered one, two or three times per day (most preferably one or two times per day). Further, the separated pharmaceutical compositions may be administered by the same or different routes of administration, preferably by the same route of administration. Most preferably the separated pharmaceutical compositions are administered orally. The first and/or the second active ingredient may be independently from each other administered according to a dose up-titration regimen up to the respective maintenance dose; the pharmaceutical compositions comprising the first and/or the second active ingredient needed for the dose up-titration will contain the amounts of active ingredient required for the different steps of the dose up-titration regimen.

47) A further embodiment of the invention relates to a pharmaceutical combination according to any one of embodiments 1) to 46) for use as a medicament.

48) A further embodiment of the invention relates to a pharmaceutical combination according to any one of embodiments 1) to 46) for use in the prevention/prophylaxis and/or treatment of a disease or disorder associated with a dysfunction of T-type calcium channels (and notably of a disease or disorder wherein the blockade of the T-type calcium channel subtypes $Ca_v3.1$, $Ca_v3.2$ and/or $Ca_v3.3$ is indicated).

49) A further embodiment of the invention relates to a pharmaceutical combination according to any one of embodiments 1) to 46) for use in the prevention/prophylaxis and/or treatment of epilepsy (notably idiopathic generalized epilepsy).

50) A further embodiment of the invention relates to a pharmaceutical combination according to any one of embodiments 1) to 46) for use in the prevention/prophylaxis and/or treatment of focal and/or generalized seizures.

51) A further embodiment of the invention relates to a pharmaceutical combination according to any one of embodiments 1) to 46) for use in the prevention/prophylaxis and/or treatment of focal, tonic, clonic, tonic clonic, absence, myoclonic and/or atonic seizures.

52) A further embodiment of the invention relates to a pharmaceutical combination according to any one of embodiments 1) to 46) for use in the prevention/prophylaxis and/or treatment of tonic clonic, absence, myoclonic and/or atonic seizures.

53) A further embodiment of the invention relates to a pharmaceutical combination according to any one of embodiments 1) to 46) for use in the prevention/prophylaxis and/or treatment of tonic clonic and/or absence seizures.

54) A further embodiment of the invention relates to a pharmaceutical combination according to any one of embodiments 1) to 46) for use in the prevention/prophylaxis and/or treatment of tonic clonic seizures.

55) A further embodiment of the invention relates to a pharmaceutical combination according to any one of embodiments 1) to 46) for use in the prevention/prophylaxis and/or treatment of absence seizures.

The term "epilepsy" describes recurrent unprovoked seizures wherein the term "seizure" refers to an excessive and/or hypersynchronous electrical neuronal activity. Different types of "seizures" are disclosed for example in Berg et al., *Epilepsia*. 2010; 51(4): 676-685, which reference is herewith incorporated by reference.

The present invention also relates to a method for the prevention/prophylaxis and/or treatment of a disease or disorder listed in any one of embodiments 48) to 55) comprising administering to a subject (preferably a human subject) in need thereof a pharmaceutically active amount of a pharmaceutical combination according to any one of embodiments 1) to 46).

56) A further embodiment of the invention relates to a pharmaceutical composition containing, as active principle, N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient, wherein the pharmaceutical composition is to be administered in combination with a second pharmaceutical composition containing, as active principle, 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine), (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), *N*-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide (Acetazolamide), (2*S*)-2-[(4*R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide (Brivaracetam), 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam), 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), (*S*)-10-acetoxy-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Eslicarbazepine acetate), (3-carbamoyloxy-2-phenylpropyl) carbamate (Felbamate), 1-(aminomethyl)cyclohexanecarboxylic acid (Gabapentin), (*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide (Lacosamide), 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'-(1'*H*)-one (Perampanel), 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), 2-(2-oxopyrrolidin-1-yl)acetamide (Piracetam), (3*S*)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin), 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone), ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate (Retigabine), 1-(2,6-difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide (Rufinamide), (*RS*)-(*E*)-4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol (Stiripentol), (3*R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (Tiagabine), 2,3:4,5-bis-O-

(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate), (*RS*)-4-aminohex-5-enoic acid (Vigabatrin), or benzo[d]isoxazol-3-ylmethanesulfonamide (Zonisamide), or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

57) A further embodiment of the invention relates to a pharmaceutical composition
 5 containing, as active principle, N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient, wherein the pharmaceutical composition is to be administered in combination with a second pharmaceutical composition containing, as active principle, (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione
 10 (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 2-propylpentanoic acid (Valproic acid), or 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

58) A further embodiment of the invention relates to a pharmaceutical composition
 15 according to embodiment 56) or 57) for use as a medicament.

59) A further embodiment of the invention relates to a pharmaceutical composition according to embodiment 56) or 57) for use in the prevention/prophylaxis and/or treatment of a disease or disorder listed in any one of embodiments 48) to 55).

60) A further embodiment of the invention relates to a pharmaceutical composition
 20 containing, as active principle, 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine), (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), *N*-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide
 25 (Acetazolamide), (2*S*)-2-[(4*R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide (Brivaracetam), 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam), 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), (*S*)-10-acetoxy-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Eslicarbazepine acetate), (3-carbamoyloxy-2-phenylpropyl) carbamate (Felbamate), 1-(aminomethyl)cyclohexanecarboxylic acid
 30 (Gabapentin), (*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide (Lacosamide), 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'(1*H*)-one (Perampanel), 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), 2-(2-oxopyrrolidin-1-yl)acetamide (Piracetam), (3*S*)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin), 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone), ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate
 35 (Retigabine), 1-(2,6-difluorobenzyl)-1*H*-1,2,3-

triazole-4-carboxamide (Rufinamide), (*RS*)-(E)-4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol (Stiripentol), (*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (Tiagabine), 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate), (*RS*)-4-aminohex-5-enoic acid (Vigabatrin), or
 5 benzo[d]isoxazol-3-ylmethanesulfonamide (Zonisamide), or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient, wherein the pharmaceutical composition is to be administered in combination with a second pharmaceutical composition containing, as active principle, N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable
 10 salt thereof, and at least one therapeutically inert excipient.

61) A further embodiment of the invention relates to a pharmaceutical composition containing, as active principle, (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 2-propylpentanoic acid (Valproic acid), or 5-(2-
 15 chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient, wherein the pharmaceutical composition is to be administered in combination with a second pharmaceutical composition containing, as active principle, N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a
 20 pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

62) A further embodiment of the invention relates to a pharmaceutical composition according to embodiment 60) or 61) for use as a medicament.

63) A further embodiment of the invention relates to a pharmaceutical composition according to embodiment 60) or 61) for use in the prevention/prophylaxis and/or treatment
 25 of a disease or disorder listed in any one of embodiments 48) to 55).

64) A further embodiment of the invention relates to a kit of parts comprising a first pharmaceutical composition containing, as active principle, N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient;
 30 and a second pharmaceutical composition containing, as active principle, 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine), (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid),
 35 *N*-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide (Acetazolamide), (2*S*)-2-[(4*R*)-2-oxo-4-

propylpyrrolidin-1-yl]butanamide (Brivaracetam), 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam), 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), (S)-10-acetoxy-10,11-dihydro-5*H*-dibenz[b,f]azepine-5-carboxamide (Eslicarbazepine acetate), (3-carbamoyloxy-2-phenylpropyl) carbamate (Felbamate), 1-(aminomethyl)cyclohexaneacetic acid (Gabapentin), (*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide (Lacosamide), 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'(¹H)-one (Perampanel), 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), 2-(2-oxopyrrolidin-1-yl)acetamide (Piracetam), (3*S*)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin), 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone), ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate (Retigabine), 1-(2,6-difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide (Rufinamide), (*RS*)-(*E*)-4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol (Stiripentol), (3*R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (Tiagabine), 2,3:4,5-bis-*O*-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate), (*RS*)-4-aminohex-5-enoic acid (Vigabatrin), or benzo[d]isoxazol-3-ylmethanesulfonamide (Zonisamide), or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

65) A further embodiment of the invention relates to a kit of parts comprising a first pharmaceutical composition containing, as active principle, *N*-[1-(5-Cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient; and a second pharmaceutical composition containing, as active principle, (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 2-propylpentanoic acid (Valproic acid), or 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

66) A further embodiment of the invention relates to a kit of parts according to embodiment 64) or 65) further comprising instructions for the simultaneous, sequential or separate administration of the pharmaceutical compositions.

67) A further embodiment of the invention relates to a kit of parts according to any one of embodiments 64) to 66) for use as a medicament.

68) A further embodiment of the invention relates to a kit of parts according to any one of embodiments 64) to 66) for use in the prevention/prophylaxis and/or treatment of a disease or disorder listed in any one of embodiments 48) to 55).

69) A further embodiment of the invention relates to the use of N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and a second active ingredient which is selected from the group consisting of 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine),
 5 (RS)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (S)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), *N*-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide (Acetazolamide), (2*S*)-2-[(4*R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide (Brivaracetam), 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam),
 10 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), (S)-10-acetoxy-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Eslicarbazepine acetate), (3-carbamoyloxy-2-phenylpropyl) carbamate (Felbamate), 1-(aminomethyl)cyclohexanecarboxylic acid (Gabapentin), (*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide (Lacosamide), 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'-(1*H*)-one (Perampanel), 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), 2-(2-oxopyrrolidin-1-yl)acetamide (Piracetam), (3*S*)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin), 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone), ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate (Retigabine), 1-(2,6-difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide (Rufinamide),
 20 (RS)-(*E*)-4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol (Stiripentol), (3*R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (Tiagabine), 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate (Topiramate), (RS)-4-amino-5-hexenoic acid (Vigabatrin), or benzo[*d*]isoxazol-3-ylmethanesulfonamide (Zonisamide), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the prevention/prophylaxis and/or treatment of a disease or disorder listed in any one of embodiments 48) to 55).

70) A further embodiment of the invention relates to the use according to embodiment 69), wherein the second active ingredient is (RS)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (S)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 2-propylpentanoic acid (Valproic acid), or 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), or a pharmaceutically acceptable salt thereof.

71) A further embodiment of the invention relates to the use of N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use, in combination with a second medicament comprising 5*H*-dibenzo[*b,f*]azepine-5-carboxamide

(Carbamazepine), (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), *N*-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide (Acetazolamide), (*2S*)-2-[(*4R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide (Brivaracetam), 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam), 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), (*S*)-10-acetoxy-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Eslicarbazepine acetate), (3-carbamoyloxy-2-phenylpropyl) carbamate (Felbamate), 1-(aminomethyl)cyclohexanecarboxylic acid (Gabapentin), (*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide (Lacosamide), 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'-(1'*H*)-one (Perampanel), 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), 2-(2-oxopyrrolidin-1-yl)acetamide (Piracetam), (*3S*)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin), 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone), ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate (Retigabine), 1-(2,6-difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide (Rufinamide), (*RS*)-(*E*)-4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol (Stiripentol), (*3R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (Tiagabine), 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate), (*RS*)-4-aminohex-5-enoic acid (Vigabatrin), or benzo[*d*]isoxazol-3-ylmethanesulfonamide (Zonisamide), or a pharmaceutically acceptable salt thereof, in the prevention/prophylaxis and/or treatment of a disease or disorder listed in any one of embodiments 48) to 55).

72) A further embodiment of the invention relates to the use according to embodiment 71), wherein the second medicament comprises (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 2-propylpentanoic acid (Valproic acid), or 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), or a pharmaceutically acceptable salt thereof.

73) A further embodiment of the invention relates to the use of 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine), (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), *N*-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide (Acetazolamide), (*2S*)-2-[(*4R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide (Brivaracetam), 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam), 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-

benzodiazepin-2-one (Clonazepam), (*S*)-10-acetoxy-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Eslicarbazepine acetate), (3-carbamoyloxy-2-phenylpropyl) carbamate (Felbamate), 1-(aminomethyl)cyclohexaneacetic acid (Gabapentin), (*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide (Lacosamide), 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'-(1'¹H)-one (Perampanel), 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), 2-(2-oxopyrrolidin-1-yl)acetamide (Piracetam), (3*S*)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin), 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone), ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate (Retigabine), 1-(2,6-difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide (Rufinamide), (*RS*)-(*E*)-4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol (Stiripentol), (3*R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (Tiagabine), 2,3:4,5-bis-*O*-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate), (*RS*)-4-aminohept-5-enoic acid (Vigabatrin), or benzo[*d*]isoxazol-3-ylmethanesulfonamide (Zonisamide), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use, in combination with a second medicament comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, in the prevention/prophylaxis and/or treatment of a disease or disorder listed in any one of embodiments 48) to 55).

74) A further embodiment of the invention relates to the use of (*RS*)-3-ethyl-3-methylpyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), 2-propylpentanoic acid (Valproic acid), or 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use, in combination with a second medicament comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, in the prevention/prophylaxis and/or treatment of a disease or disorder listed in any one of embodiments 48) to 55).

Based on the dependencies of the different embodiments 1) to 74) as disclosed hereinabove, the following embodiments are thus possible and intended and herewith specifically disclosed in individualised form: 1, 2+1, 3+1, 4+1, 5+1, 6+1, 7+1, 8+1, 9+1, 10+1, 11+1, 12+1, 13+1, 14+1, 15+1, 16+1, 17+1, 18+1, 19+1, 20+1, 21+1, 22+1, 23+1, 24+1, 25+1, 26+1, 27+1, 28+1, 29+1, 30+1, 31+1, 32+1, 33+1, 34+1, 35+1, 36+1, 37+1, 38+1, 39+1, 40+1, 41+1, 42+1, 43+1, 44+1, 45+1, 45+2+1, 45+3+1, 45+4+1, 45+5+1, 45+6+1, 45+7+1, 45+8+1, 45+9+1, 45+10+1, 45+11+1, 45+12+1, 45+13+1, 45+14+1, 45+15+1, 45+16+1, 45+17+1, 45+18+1, 45+19+1, 45+20+1, 45+21+1, 45+22+1, 45+23+1, 45+24+1, 45+25+1, 45+26+1, 45+27+1, 45+28+1, 45+29+1, 45+30+1, 45+31+1, 45+32+1, 45+33+1, 45+34+1, 45+35+1, 45+36+1, 45+37+1, 45+38+1, 45+39+1, 45+40+1, 45+41+1, 45+42+1, 45+43+1, 45+44+1, 46+1, 46+2+1,

- 46+3+1, 46+4+1, 46+5+1, 46+6+1, 46+7+1, 46+8+1, 46+9+1, 46+10+1, 46+11+1, 46+12+1, 46+13+1, 46+14+1, 46+15+1, 46+16+1, 46+17+1, 46+18+1, 46+19+1, 46+20+1, 46+21+1, 46+22+1, 46+23+1, 46+24+1, 46+25+1, 46+26+1, 46+27+1, 46+28+1, 46+29+1, 46+30+1, 46+31+1, 46+32+1, 46+33+1, 46+34+1, 46+35+1, 46+36+1, 46+37+1, 46+38+1, 46+39+1, 46+40+1, 46+41+1, 46+42+1, 46+43+1, 46+44+1, 47+1, 47+2+1, 5 47+3+1, 47+4+1, 47+5+1, 47+6+1, 47+7+1, 47+8+1, 47+9+1, 47+10+1, 47+11+1, 47+12+1, 47+13+1, 47+14+1, 47+15+1, 47+16+1, 47+17+1, 47+18+1, 47+19+1, 47+20+1, 47+21+1, 47+22+1, 47+23+1, 47+24+1, 47+25+1, 47+26+1, 47+27+1, 47+28+1, 47+29+1, 47+30+1, 47+31+1, 47+32+1, 47+33+1, 47+34+1, 47+35+1, 47+36+1, 47+37+1, 47+38+1, 47+39+1, 47+40+1, 47+41+1, 47+42+1, 47+43+1, 47+44+1, 47+45+1, 47+45+2+1, 47+45+3+1, 47+45+4+1, 47+45+5+1, 47+45+6+1, 47+45+7+1, 47+45+8+1, 47+45+9+1, 10 47+45+10+1, 47+45+11+1, 47+45+12+1, 47+45+13+1, 47+45+14+1, 47+45+15+1, 47+45+16+1, 47+45+17+1, 47+45+18+1, 47+45+19+1, 47+45+20+1, 47+45+21+1, 47+45+22+1, 47+45+23+1, 47+45+24+1, 47+45+25+1, 47+45+26+1, 47+45+27+1, 47+45+28+1, 47+45+29+1, 47+45+30+1, 47+45+31+1, 47+45+32+1, 47+45+33+1, 47+45+34+1, 47+45+35+1, 47+45+36+1, 47+45+37+1, 47+45+38+1, 47+45+39+1, 47+45+40+1, 47+45+41+1, 47+45+42+1, 47+45+43+1, 47+45+44+1, 47+46+1, 47+46+2+1, 47+46+3+1, 47+46+4+1, 47+46+5+1, 15 47+46+6+1, 47+46+7+1, 47+46+8+1, 47+46+9+1, 47+46+10+1, 47+46+11+1, 47+46+12+1, 47+46+13+1, 47+46+14+1, 47+46+15+1, 47+46+16+1, 47+46+17+1, 47+46+18+1, 47+46+19+1, 47+46+20+1, 47+46+21+1, 47+46+22+1, 47+46+23+1, 47+46+24+1, 47+46+25+1, 47+46+26+1, 47+46+27+1, 47+46+28+1, 47+46+29+1, 47+46+30+1, 47+46+31+1, 47+46+32+1, 47+46+33+1, 47+46+34+1, 47+46+35+1, 47+46+36+1, 47+46+37+1, 47+46+38+1, 47+46+39+1, 47+46+40+1, 47+46+41+1, 47+46+42+1, 47+46+43+1, 47+46+44+1, 48+1, 20 48+2+1, 48+3+1, 48+4+1, 48+5+1, 48+6+1, 48+7+1, 48+8+1, 48+9+1, 48+10+1, 48+11+1, 48+12+1, 48+13+1, 48+14+1, 48+15+1, 48+16+1, 48+17+1, 48+18+1, 48+19+1, 48+20+1, 48+21+1, 48+22+1, 48+23+1, 48+24+1, 48+25+1, 48+26+1, 48+27+1, 48+28+1, 48+29+1, 48+30+1, 48+31+1, 48+32+1, 48+33+1, 48+34+1, 48+35+1, 48+36+1, 48+37+1, 48+38+1, 48+39+1, 48+40+1, 48+41+1, 48+42+1, 48+43+1, 48+44+1, 48+45+1, 48+45+2+1, 48+45+3+1, 48+45+4+1, 48+45+5+1, 48+45+6+1, 48+45+7+1, 48+45+8+1, 48+45+9+1, 25 48+45+10+1, 48+45+11+1, 48+45+12+1, 48+45+13+1, 48+45+14+1, 48+45+15+1, 48+45+16+1, 48+45+17+1, 48+45+18+1, 48+45+19+1, 48+45+20+1, 48+45+21+1, 48+45+22+1, 48+45+23+1, 48+45+24+1, 48+45+25+1, 48+45+26+1, 48+45+27+1, 48+45+28+1, 48+45+29+1, 48+45+30+1, 48+45+31+1, 48+45+32+1, 48+45+33+1, 48+45+34+1, 48+45+35+1, 48+45+36+1, 48+45+37+1, 48+45+38+1, 48+45+39+1, 48+45+40+1, 48+45+41+1, 48+45+42+1, 48+45+43+1, 48+45+44+1, 48+46+1, 48+46+2+1, 48+46+3+1, 48+46+4+1, 48+46+5+1, 30 48+46+6+1, 48+46+7+1, 48+46+8+1, 48+46+9+1, 48+46+10+1, 48+46+11+1, 48+46+12+1, 48+46+13+1, 48+46+14+1, 48+46+15+1, 48+46+16+1, 48+46+17+1, 48+46+18+1, 48+46+19+1, 48+46+20+1, 48+46+21+1, 48+46+22+1, 48+46+23+1, 48+46+24+1, 48+46+25+1, 48+46+26+1, 48+46+27+1, 48+46+28+1, 48+46+29+1, 48+46+30+1, 48+46+31+1, 48+46+32+1, 48+46+33+1, 48+46+34+1, 48+46+35+1, 48+46+36+1, 48+46+37+1, 48+46+38+1, 48+46+39+1, 48+46+40+1, 48+46+41+1, 48+46+42+1, 48+46+43+1, 48+46+44+1, 49+1, 35 49+2+1, 49+3+1, 49+4+1, 49+5+1, 49+6+1, 49+7+1, 49+8+1, 49+9+1, 49+10+1, 49+11+1, 49+12+1, 49+13+1, 49+14+1, 49+15+1, 49+16+1, 49+17+1, 49+18+1, 49+19+1, 49+20+1, 49+21+1, 49+22+1, 49+23+1, 49+24+1, 49+25+1, 49+26+1, 49+27+1, 49+28+1, 49+29+1, 49+30+1, 49+31+1, 49+32+1, 49+33+1, 49+34+1, 49+35+1,

- 49+36+1, 49+37+1, 49+38+1, 49+39+1, 49+40+1, 49+41+1, 49+42+1, 49+43+1, 49+44+1, 49+45+1, 49+45+2+1, 49+45+3+1, 49+45+4+1, 49+45+5+1, 49+45+6+1, 49+45+7+1, 49+45+8+1, 49+45+9+1, 49+45+10+1, 49+45+11+1, 49+45+12+1, 49+45+13+1, 49+45+14+1, 49+45+15+1, 49+45+16+1, 49+45+17+1, 49+45+18+1, 49+45+19+1, 49+45+20+1, 49+45+21+1, 49+45+22+1, 49+45+23+1, 49+45+24+1, 49+45+25+1,
- 5 49+45+26+1, 49+45+27+1, 49+45+28+1, 49+45+29+1, 49+45+30+1, 49+45+31+1, 49+45+32+1, 49+45+33+1, 49+45+34+1, 49+45+35+1, 49+45+36+1, 49+45+37+1, 49+45+38+1, 49+45+39+1, 49+45+40+1, 49+45+41+1, 49+45+42+1, 49+45+43+1, 49+45+44+1, 49+46+1, 49+46+2+1, 49+46+3+1, 49+46+4+1, 49+46+5+1, 49+46+6+1, 49+46+7+1, 49+46+8+1, 49+46+9+1, 49+46+10+1, 49+46+11+1, 49+46+12+1, 49+46+13+1, 49+46+14+1, 49+46+15+1, 49+46+16+1, 49+46+17+1, 49+46+18+1, 49+46+19+1, 49+46+20+1, 49+46+21+1,
- 10 49+46+22+1, 49+46+23+1, 49+46+24+1, 49+46+25+1, 49+46+26+1, 49+46+27+1, 49+46+28+1, 49+46+29+1, 49+46+30+1, 49+46+31+1, 49+46+32+1, 49+46+33+1, 49+46+34+1, 49+46+35+1, 49+46+36+1, 49+46+37+1, 49+46+38+1, 49+46+39+1, 49+46+40+1, 49+46+41+1, 49+46+42+1, 49+46+43+1, 49+46+44+1, 50+1, 50+2+1, 50+3+1, 50+4+1, 50+5+1, 50+6+1, 50+7+1, 50+8+1, 50+9+1, 50+10+1, 50+11+1, 50+12+1, 50+13+1, 50+14+1, 50+15+1, 50+16+1, 50+17+1, 50+18+1, 50+19+1, 50+20+1, 50+21+1, 50+22+1, 50+23+1, 50+24+1,
- 15 50+25+1, 50+26+1, 50+27+1, 50+28+1, 50+29+1, 50+30+1, 50+31+1, 50+32+1, 50+33+1, 50+34+1, 50+35+1, 50+36+1, 50+37+1, 50+38+1, 50+39+1, 50+40+1, 50+41+1, 50+42+1, 50+43+1, 50+44+1, 50+45+1, 50+45+2+1, 50+45+3+1, 50+45+4+1, 50+45+5+1, 50+45+6+1, 50+45+7+1, 50+45+8+1, 50+45+9+1, 50+45+10+1, 50+45+11+1, 50+45+12+1, 50+45+13+1, 50+45+14+1, 50+45+15+1, 50+45+16+1, 50+45+17+1, 50+45+18+1, 50+45+19+1, 50+45+20+1, 50+45+21+1, 50+45+22+1, 50+45+23+1, 50+45+24+1, 50+45+25+1,
- 20 50+45+26+1, 50+45+27+1, 50+45+28+1, 50+45+29+1, 50+45+30+1, 50+45+31+1, 50+45+32+1, 50+45+33+1, 50+45+34+1, 50+45+35+1, 50+45+36+1, 50+45+37+1, 50+45+38+1, 50+45+39+1, 50+45+40+1, 50+45+41+1, 50+45+42+1, 50+45+43+1, 50+45+44+1, 50+46+1, 50+46+2+1, 50+46+3+1, 50+46+4+1, 50+46+5+1, 50+46+6+1, 50+46+7+1, 50+46+8+1, 50+46+9+1, 50+46+10+1, 50+46+11+1, 50+46+12+1, 50+46+13+1, 50+46+14+1, 50+46+15+1, 50+46+16+1, 50+46+17+1, 50+46+18+1, 50+46+19+1, 50+46+20+1, 50+46+21+1,
- 25 50+46+22+1, 50+46+23+1, 50+46+24+1, 50+46+25+1, 50+46+26+1, 50+46+27+1, 50+46+28+1, 50+46+29+1, 50+46+30+1, 50+46+31+1, 50+46+32+1, 50+46+33+1, 50+46+34+1, 50+46+35+1, 50+46+36+1, 50+46+37+1, 50+46+38+1, 50+46+39+1, 50+46+40+1, 50+46+41+1, 50+46+42+1, 50+46+43+1, 50+46+44+1, 51+1, 51+2+1, 51+3+1, 51+4+1, 51+5+1, 51+6+1, 51+7+1, 51+8+1, 51+9+1, 51+10+1, 51+11+1, 51+12+1, 51+13+1, 51+14+1, 51+15+1, 51+16+1, 51+17+1, 51+18+1, 51+19+1, 51+20+1, 51+21+1, 51+22+1, 51+23+1, 51+24+1,
- 30 51+25+1, 51+26+1, 51+27+1, 51+28+1, 51+29+1, 51+30+1, 51+31+1, 51+32+1, 51+33+1, 51+34+1, 51+35+1, 51+36+1, 51+37+1, 51+38+1, 51+39+1, 51+40+1, 51+41+1, 51+42+1, 51+43+1, 51+44+1, 51+45+1, 51+45+2+1, 51+45+3+1, 51+45+4+1, 51+45+5+1, 51+45+6+1, 51+45+7+1, 51+45+8+1, 51+45+9+1, 51+45+10+1, 51+45+11+1, 51+45+12+1, 51+45+13+1, 51+45+14+1, 51+45+15+1, 51+45+16+1, 51+45+17+1, 51+45+18+1, 51+45+19+1, 51+45+20+1, 51+45+21+1, 51+45+22+1, 51+45+23+1, 51+45+24+1, 51+45+25+1,
- 35 51+45+26+1, 51+45+27+1, 51+45+28+1, 51+45+29+1, 51+45+30+1, 51+45+31+1, 51+45+32+1, 51+45+33+1, 51+45+34+1, 51+45+35+1, 51+45+36+1, 51+45+37+1, 51+45+38+1, 51+45+39+1, 51+45+40+1, 51+45+41+1, 51+45+42+1, 51+45+43+1, 51+45+44+1, 51+46+1, 51+46+2+1, 51+46+3+1, 51+46+4+1, 51+46+5+1,

- 51+46+6+1, 51+46+7+1, 51+46+8+1, 51+46+9+1, 51+46+10+1, 51+46+11+1, 51+46+12+1, 51+46+13+1, 51+46+14+1, 51+46+15+1, 51+46+16+1, 51+46+17+1, 51+46+18+1, 51+46+19+1, 51+46+20+1, 51+46+21+1, 51+46+22+1, 51+46+23+1, 51+46+24+1, 51+46+25+1, 51+46+26+1, 51+46+27+1, 51+46+28+1, 51+46+29+1, 51+46+30+1, 51+46+31+1, 51+46+32+1, 51+46+33+1, 51+46+34+1, 51+46+35+1, 51+46+36+1, 51+46+37+1,
- 5 51+46+38+1, 51+46+39+1, 51+46+40+1, 51+46+41+1, 51+46+42+1, 51+46+43+1, 51+46+44+1, 52+1, 52+2+1, 52+3+1, 52+4+1, 52+5+1, 52+6+1, 52+7+1, 52+8+1, 52+9+1, 52+10+1, 52+11+1, 52+12+1, 52+13+1, 52+14+1, 52+15+1, 52+16+1, 52+17+1, 52+18+1, 52+19+1, 52+20+1, 52+21+1, 52+22+1, 52+23+1, 52+24+1, 52+25+1, 52+26+1, 52+27+1, 52+28+1, 52+29+1, 52+30+1, 52+31+1, 52+32+1, 52+33+1, 52+34+1, 52+35+1, 52+36+1, 52+37+1, 52+38+1, 52+39+1, 52+40+1, 52+41+1, 52+42+1, 52+43+1, 52+44+1, 52+45+1,
- 10 52+45+2+1, 52+45+3+1, 52+45+4+1, 52+45+5+1, 52+45+6+1, 52+45+7+1, 52+45+8+1, 52+45+9+1, 52+45+10+1, 52+45+11+1, 52+45+12+1, 52+45+13+1, 52+45+14+1, 52+45+15+1, 52+45+16+1, 52+45+17+1, 52+45+18+1, 52+45+19+1, 52+45+20+1, 52+45+21+1, 52+45+22+1, 52+45+23+1, 52+45+24+1, 52+45+25+1, 52+45+26+1, 52+45+27+1, 52+45+28+1, 52+45+29+1, 52+45+30+1, 52+45+31+1, 52+45+32+1, 52+45+33+1, 52+45+34+1, 52+45+35+1, 52+45+36+1, 52+45+37+1, 52+45+38+1, 52+45+39+1, 52+45+40+1, 52+45+41+1,
- 15 52+45+42+1, 52+45+43+1, 52+45+44+1, 52+46+1, 52+46+2+1, 52+46+3+1, 52+46+4+1, 52+46+5+1, 52+46+6+1, 52+46+7+1, 52+46+8+1, 52+46+9+1, 52+46+10+1, 52+46+11+1, 52+46+12+1, 52+46+13+1, 52+46+14+1, 52+46+15+1, 52+46+16+1, 52+46+17+1, 52+46+18+1, 52+46+19+1, 52+46+20+1, 52+46+21+1, 52+46+22+1, 52+46+23+1, 52+46+24+1, 52+46+25+1, 52+46+26+1, 52+46+27+1, 52+46+28+1, 52+46+29+1, 52+46+30+1, 52+46+31+1, 52+46+32+1, 52+46+33+1, 52+46+34+1, 52+46+35+1, 52+46+36+1, 52+46+37+1,
- 20 52+46+38+1, 52+46+39+1, 52+46+40+1, 52+46+41+1, 52+46+42+1, 52+46+43+1, 52+46+44+1, 53+1, 53+2+1, 53+3+1, 53+4+1, 53+5+1, 53+6+1, 53+7+1, 53+8+1, 53+9+1, 53+10+1, 53+11+1, 53+12+1, 53+13+1, 53+14+1, 53+15+1, 53+16+1, 53+17+1, 53+18+1, 53+19+1, 53+20+1, 53+21+1, 53+22+1, 53+23+1, 53+24+1, 53+25+1, 53+26+1, 53+27+1, 53+28+1, 53+29+1, 53+30+1, 53+31+1, 53+32+1, 53+33+1, 53+34+1, 53+35+1, 53+36+1, 53+37+1, 53+38+1, 53+39+1, 53+40+1, 53+41+1, 53+42+1, 53+43+1, 53+44+1, 53+45+1,
- 25 53+45+2+1, 53+45+3+1, 53+45+4+1, 53+45+5+1, 53+45+6+1, 53+45+7+1, 53+45+8+1, 53+45+9+1, 53+45+10+1, 53+45+11+1, 53+45+12+1, 53+45+13+1, 53+45+14+1, 53+45+15+1, 53+45+16+1, 53+45+17+1, 53+45+18+1, 53+45+19+1, 53+45+20+1, 53+45+21+1, 53+45+22+1, 53+45+23+1, 53+45+24+1, 53+45+25+1, 53+45+26+1, 53+45+27+1, 53+45+28+1, 53+45+29+1, 53+45+30+1, 53+45+31+1, 53+45+32+1, 53+45+33+1, 53+45+34+1, 53+45+35+1, 53+45+36+1, 53+45+37+1, 53+45+38+1, 53+45+39+1, 53+45+40+1, 53+45+41+1,
- 30 53+45+42+1, 53+45+43+1, 53+45+44+1, 53+46+1, 53+46+2+1, 53+46+3+1, 53+46+4+1, 53+46+5+1, 53+46+6+1, 53+46+7+1, 53+46+8+1, 53+46+9+1, 53+46+10+1, 53+46+11+1, 53+46+12+1, 53+46+13+1, 53+46+14+1, 53+46+15+1, 53+46+16+1, 53+46+17+1, 53+46+18+1, 53+46+19+1, 53+46+20+1, 53+46+21+1, 53+46+22+1, 53+46+23+1, 53+46+24+1, 53+46+25+1, 53+46+26+1, 53+46+27+1, 53+46+28+1, 53+46+29+1, 53+46+30+1, 53+46+31+1, 53+46+32+1, 53+46+33+1, 53+46+34+1, 53+46+35+1, 53+46+36+1, 53+46+37+1,
- 35 53+46+38+1, 53+46+39+1, 53+46+40+1, 53+46+41+1, 53+46+42+1, 53+46+43+1, 53+46+44+1, 54+1, 54+2+1, 54+3+1, 54+4+1, 54+5+1, 54+6+1, 54+7+1, 54+8+1, 54+9+1, 54+10+1, 54+11+1, 54+12+1, 54+13+1, 54+14+1, 54+15+1, 54+16+1, 54+17+1, 54+18+1, 54+19+1, 54+20+1, 54+21+1, 54+22+1, 54+23+1, 54+24+1,

- 54+25+1, 54+26+1, 54+27+1, 54+28+1, 54+29+1, 54+30+1, 54+31+1, 54+32+1, 54+33+1, 54+34+1, 54+35+1, 54+36+1, 54+37+1, 54+38+1, 54+39+1, 54+40+1, 54+41+1, 54+42+1, 54+43+1, 54+44+1, 54+45+1, 54+45+2+1, 54+45+3+1, 54+45+4+1, 54+45+5+1, 54+45+6+1, 54+45+7+1, 54+45+8+1, 54+45+9+1, 54+45+10+1, 54+45+11+1, 54+45+12+1, 54+45+13+1, 54+45+14+1, 54+45+15+1, 54+45+16+1, 54+45+17+1, 54+45+18+1, 54+45+19+1, 54+45+20+1, 54+45+21+1, 54+45+22+1, 54+45+23+1, 54+45+24+1, 54+45+25+1, 54+45+26+1, 54+45+27+1, 54+45+28+1, 54+45+29+1, 54+45+30+1, 54+45+31+1, 54+45+32+1, 54+45+33+1, 54+45+34+1, 54+45+35+1, 54+45+36+1, 54+45+37+1, 54+45+38+1, 54+45+39+1, 54+45+40+1, 54+45+41+1, 54+45+42+1, 54+45+43+1, 54+45+44+1, 54+46+1, 54+46+2+1, 54+46+3+1, 54+46+4+1, 54+46+5+1, 54+46+6+1, 54+46+7+1, 54+46+8+1, 54+46+9+1, 54+46+10+1, 54+46+11+1, 54+46+12+1, 54+46+13+1, 54+46+14+1, 54+46+15+1, 54+46+16+1, 54+46+17+1, 54+46+18+1, 54+46+19+1, 54+46+20+1, 54+46+21+1, 54+46+22+1, 54+46+23+1, 54+46+24+1, 54+46+25+1, 54+46+26+1, 54+46+27+1, 54+46+28+1, 54+46+29+1, 54+46+30+1, 54+46+31+1, 54+46+32+1, 54+46+33+1, 54+46+34+1, 54+46+35+1, 54+46+36+1, 54+46+37+1, 54+46+38+1, 54+46+39+1, 54+46+40+1, 54+46+41+1, 54+46+42+1, 54+46+43+1, 54+46+44+1, 55+1, 55+2+1, 55+3+1, 55+4+1, 55+5+1, 55+6+1, 55+7+1, 55+8+1, 55+9+1, 55+10+1, 55+11+1, 55+12+1, 55+13+1, 55+14+1, 55+15+1, 55+16+1, 55+17+1, 55+18+1, 55+19+1, 55+20+1, 55+21+1, 55+22+1, 55+23+1, 55+24+1, 55+25+1, 55+26+1, 55+27+1, 55+28+1, 55+29+1, 55+30+1, 55+31+1, 55+32+1, 55+33+1, 55+34+1, 55+35+1, 55+36+1, 55+37+1, 55+38+1, 55+39+1, 55+40+1, 55+41+1, 55+42+1, 55+43+1, 55+44+1, 55+45+1, 55+45+2+1, 55+45+3+1, 55+45+4+1, 55+45+5+1, 55+45+6+1, 55+45+7+1, 55+45+8+1, 55+45+9+1, 55+45+10+1, 55+45+11+1, 55+45+12+1, 55+45+13+1, 55+45+14+1, 55+45+15+1, 55+45+16+1, 55+45+17+1, 55+45+18+1, 55+45+19+1, 55+45+20+1, 55+45+21+1, 55+45+22+1, 55+45+23+1, 55+45+24+1, 55+45+25+1, 55+45+26+1, 55+45+27+1, 55+45+28+1, 55+45+29+1, 55+45+30+1, 55+45+31+1, 55+45+32+1, 55+45+33+1, 55+45+34+1, 55+45+35+1, 55+45+36+1, 55+45+37+1, 55+45+38+1, 55+45+39+1, 55+45+40+1, 55+45+41+1, 55+45+42+1, 55+45+43+1, 55+45+44+1, 55+46+1, 55+46+2+1, 55+46+3+1, 55+46+4+1, 55+46+5+1, 55+46+6+1, 55+46+7+1, 55+46+8+1, 55+46+9+1, 55+46+10+1, 55+46+11+1, 55+46+12+1, 55+46+13+1, 55+46+14+1, 55+46+15+1, 55+46+16+1, 55+46+17+1, 55+46+18+1, 55+46+19+1, 55+46+20+1, 55+46+21+1, 55+46+22+1, 55+46+23+1, 55+46+24+1, 55+46+25+1, 55+46+26+1, 55+46+27+1, 55+46+28+1, 55+46+29+1, 55+46+30+1, 55+46+31+1, 55+46+32+1, 55+46+33+1, 55+46+34+1, 55+46+35+1, 55+46+36+1, 55+46+37+1, 55+46+38+1, 55+46+39+1, 55+46+40+1, 55+46+41+1, 55+46+42+1, 55+46+43+1, 55+46+44+1, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66+64, 66+65, 67, 68, 69, 70+69, 71, 72+71, 73, and 74;
- In the list above the numbers refer to the embodiments according to their numbering provided hereinabove whereas “+” indicates the dependency from another embodiment. The different individualised embodiments are separated by commas. In other words, “45+2+1” for example refers to embodiment 45) depending on embodiment 2), depending on embodiment 1), i.e. embodiment “45+2+1” corresponds to the pharmaceutical combination of embodiment 1) further limited by the features of the embodiments 2) and 45).

Definitions provided herein are intended to apply uniformly to the subject matter as defined in any one of embodiments 1) to 74), and, mutatis mutandis, throughout the description and the claims unless an otherwise expressly set out definition provides a broader or narrower definition. It is well understood that a definition or preferred definition of a term or expression defines and may replace the respective term or expression independently of (and in combination with) any definition or preferred definition of any or all other terms or expressions as defined herein.

Any reference to an active ingredient as defined in any one of embodiments 1) to 74) is to be understood as referring also to the pharmaceutically acceptable salts of such active ingredient, as appropriate and expedient.

The term "pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. Such salts include inorganic or organic acid and/or base addition salts depending on the presence of basic and/or acidic groups in the subject compound. For reference see for example 'Handbook of Pharmaceutical Salts. Properties, Selection and Use.', P. Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008 and 'Pharmaceutical Salts and Co-crystals', Johan Wouters and Luc Quéré (Eds.), RSC Publishing, 2012.

The term "pharmaceutical combination", as used herein, refers to a combination of two or more, preferably two, active ingredients, wherein the active ingredients are comprised in a single pharmaceutical composition or in separated pharmaceutical compositions.

The term "active ingredient", as used herein, refers to the pharmaceutically active component of a pharmaceutical composition. Examples of active ingredients, as used herein, are in a first group N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide (COMPOUND 1), or a pharmaceutically acceptable salt thereof, and in a second group 5*H*-dibenzo[*b,f*]azepine-5-carboxamide (Carbamazepine), (*RS*)-3-ethyl-3-methyl-pyrrolidine-2,5-dione (Ethosuximide), 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (Lamotrigine), (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam), 10,11-dihydro-10-oxo-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Oxcarbazepine), 2-propylpentanoic acid (Valproic acid), *N*-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide (Acetazolamide), (2*S*)-2-[(4*R*)-2-oxo-4-propylpyrrolidin-1-yl]butanamide (Brivaracetam), 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione (Clobazam), 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one (Clonazepam), (*S*)-10-acetoxy-10,11-dihydro-5*H*-dibenz[*b,f*]azepine-5-carboxamide (Eslicarbazepine acetate), (3-carbamoyloxy-2-phenylpropyl) carbamate (Felbamate), 1-(aminomethyl)cyclohexanecarboxylic acid (Gabapentin), (*R*)-2-acetamido-*N*-benzyl-3-methoxypropanamide (Lacosamide), 5'-(2-

cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'(1'H)-one (Perampanel), 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione (Phenobarbital), 5,5-diphenylimidazolidine-2,4-dione (Phenytoin), 2-(2-oxopyrrolidin-1-yl)acetamide (Piracetam), (3*S*)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin), 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione (Primidone), ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate (Retigabine), 1-(2,6-difluorobenzyl)-1*H*-1,2,3-triazole-4-carboxamide (Rufinamide), (*RS*)-(*E*)-4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol (Stiripentol), (3*R*)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid (Tiagabine), 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate (Topiramate), (*RS*)-4-aminohex-5-enoic acid (Vigabatrin), or benzo[d]isoxazol-3-ylmethanesulfonamide (Zonisamide), or a pharmaceutically acceptable salt thereof. For the sake of clarity, an "active ingredient which has an anti-epileptic effect" is an active ingredient that can be used in the prevention/prophylaxis and/or treatment of epileptic seizures in a patient by partially or totally suppressing clinical or electrographic signs of seizures.

The term "simultaneous" or "simultaneously", when used in relation to the administration of active ingredients or of pharmaceutical compositions, means that the administration of a first active ingredient (or of a first pharmaceutical composition, respectively) is still ongoing when the administration of a second active ingredient (or of a second pharmaceutical composition, respectively) is started. Especially, the term "simultaneous" or "simultaneously" means that two active ingredients (or two pharmaceutical compositions, respectively) are administered at the same time, i.e. with the same starting and end time, as is for instance the case for the administration of two active ingredients comprised in a single pharmaceutical composition.

The term "sequential" or "sequentially", when used in relation to the administration of active ingredients or of pharmaceutical compositions, means that the administration of a second active ingredient (or of a second pharmaceutical composition, respectively) is started less than one hour after the administration of a first active ingredient (or of a first pharmaceutical composition, respectively) has been finalized.

The term "separate" or "separately", when used in relation to the administration of active ingredients or of pharmaceutical compositions, means that the administration of a second active ingredient (or of a second pharmaceutical composition, respectively) is started one hour or more (and up to about twelve hours, or up to about 24 hours) after the last preceding administration of a first active ingredient (or of a first pharmaceutical composition, respectively) has been finalized.

The expressions "to be administered in combination" or "for use, in combination" mean simultaneous, sequential or separate, preferably sequential, administration of active ingredients or pharmaceutical compositions.

5 The term "route of administration", as used herein, refers to the path by which an active ingredient (e.g. in form of a pharmaceutical composition in a particular dosage form) enters the body. The active ingredients may be administered by enteral (especially oral) or parenteral administration (including topical application or inhalation). Examples of dosage forms which may be used for the administration of the active ingredients are tablets, capsules, pills, granules, powders, solutions, suspensions, emulsions, injectable aqueous
10 or oily solutions or suspensions, suppositories, creams, gels, ear or eye drops, nasal spray, skin patches, or aerosols. Dosage forms for oral administration, such as tablets, capsules, pills, solutions or suspensions are preferred. In case the two active ingredients are comprised in separated pharmaceutical compositions, said separated pharmaceutical compositions may be administered by the same or different routes of administration using
15 the same or different dosage forms.

The production of pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams & Wilkins]) by bringing COMPOUND 1 or a
20 pharmaceutically acceptable salt thereof and/or a second active ingredient which has an anti-epileptic effect, as defined in any one of embodiments 1) to 44), or a pharmaceutically acceptable salt thereof, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual
25 pharmaceutical adjuvants.

The optimal dosing regimen (i.e., the magnitude of the dose and the dosing frequency) for each of the two active ingredients of the pharmaceutical combination according to the present invention may vary depending upon the route of administration, the dosage form, the type of epilepsy to be treated, and the particular second active ingredient applied.
30 Further, the dose and/or the dosing frequency may be different during the initial phase and the later phase of the treatment for the first and/or the second active ingredient of the pharmaceutical combination. Usually the treatment starts with low dose which is up-titrated during a period which varies for each anti-epileptic drug and continues with a maintenance dose that is typically adapted for each patient and should be the lowest dose that provides
35 seizure freedom (Perucca E et al. (2011) The pharmacological treatment of epilepsy in

adults. Lancet Neurol 10:446-456; Goldenberg MM (2010) Overview of Drugs Used For Epilepsy and Seizures. Pharmacy and Therapeutics 35(7): 392-415). A preferred maintenance dose for COMPOUND 1 is 5 to 600 mg orally once daily, especially 10 to 400 mg (preferred 20 to 400 mg) orally once daily, and notably 10 to 200 mg (preferred 40 to 200 mg) orally once daily.

The present invention also includes isotopically labelled, especially ^2H (deuterium) labelled active ingredients, which active ingredients are identical to the active ingredients as defined in any one of embodiments 1) to 44) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Isotopically labelled, especially ^2H (deuterium) labelled active ingredients and pharmaceutically acceptable salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope ^2H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile. In one embodiment only one of the two active ingredients of the pharmaceutical combination is isotopically labelled. In a preferred embodiment of the invention, the active ingredients are not isotopically labelled, or one active ingredient is not isotopically labelled and the other active ingredient is labelled only with one or more deuterium atoms, or both active ingredients are each labelled only with one or more deuterium atoms. In a most preferred embodiment, the active ingredients are not isotopically labelled at all. Isotopically labelled active ingredients may be prepared in analogy to the methods described for the not isotopically labelled active ingredients, but using the appropriate isotopic variation of suitable reagents or starting materials.

The term "about" placed before a numerical value "X" refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X.

Experimental Part:

Preparation of COMPOUND 1:

COMPOUND 1 can be prepared according to the procedure as disclosed in WO 2015/186056 or in DOI: 10.1021/acs.jmedchem.7b01236. (Bezencon O. et al., J. Med. Chem. (2017)).

Audiogenic seizure-sensitive juvenile DBA/2J mouse model of generalized tonic-clonic seizures

The inbred DBA/2J mouse strain carries an increased general susceptibility for acute generalized convulsive seizures induced by either pharmacological, electrical or, as

juvenile, auditory stimuli. At the age of 17 to 28 days (juvenile), they show tonic-clonic convulsions when exposed to a loud tone.

Male juvenile DBA/2J mice (22-24 days old, body weight between 6.6 and 14.5 grams) were used. Each mouse was placed individually in the exposure chamber, an hemispheric acrylic glass dome (diameter: 50 cm) within a sound-attenuated box. After 60 seconds of habituation, an auditory stimulus of mixed frequency tone (15-20 kHz at 110 dB) was played from a speaker placed on the top center of the dome. The stimulus was applied for 60 seconds maximum or until the mouse showed tonic extension of the hind limbs.

The sound-attenuated box was equipped with lights and a camera system in order to observe and record the behavioral seizure response classified as following:

- stage 0, no response
- stage 1, wild running
- stage 2, clonus
- stage 3, tonic extension of the hind limbs.

At the end of the experiment, all mice were euthanized by CO₂ inhalation to assess plasma and brain concentrations of drugs and the absence of pharmacokinetic interaction. Briefly, blood was sampled from the vena cava caudalis with a syringe pre-filled with EDTA (ethylenediamine tetraacetic acid) as anticoagulant and centrifuged to yield plasma (for 10 minutes, at 4°C and 5000 rpm (rounds per minute)). Brain was sampled and homogenized into one volume of cold phosphate buffer (pH 7.4). Following extraction with methanol, concentrations of the compound in plasma and brain were determined using liquid chromatography coupled to mass spectrometry.

Different combination efficacy experiments are performed. Three different first line antiepileptic drugs (i.e. valproic acid (VPA), levetiracetam (LEV) or lamotrigine (LTG)), referred as anti-epileptic drugs (AEDs) below) were used in combination with N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide (COMPOUND 1). Each experiment consists of four treatment groups:

1. Vehicle (10% Polyethylene glycol400 (PEG400) / 90% methylcellulose (0.5% in water; MC0.5 %)), 3h before exposure to the auditory stimulus + vehicle, 1h before exposure to the auditory stimulus;
2. COMPOUND 1 (in 10% PEG400 / 90% MC0.5 %), 3h before exposure to the auditory stimulus + vehicle, 1h before exposure to the auditory stimulus;
3. Vehicle, 3h before exposure to the auditory stimulus + AED (in 10% PEG400 / 90% MC0.5 %), 1h before exposure to the auditory stimulus; and

4. COMPOUND 1 (in 10% PEG400 / 90% MC0.5 %), 3h before exposure to the auditory stimulus + AED (in 10% PEG400 / 90% MC0.5 %), 1h before exposure to the auditory stimulus.

The results from the combination efficacy experiments using COMPOUND 1 and valproic acid (VPA) are shown in Table 1.

Table 1: Efficacy of COMPOUND 1, VPA or its combination in audiogenic seizure-sensitive juvenile DBA/2J mice, a model of generalized convulsive seizures (n=9-10/group) with corresponding brain and plasma concentration.

Species		Juvenile male audiogenic seizure-sensitive DBA/2J mice (n = 9-10)			
Administration		Oral gavage, 5 mL/kg in 10 % PEG400 / 90 % MC0.5 %			
Assessment		Maximal seizure stage observed during exposure to auditory stimulus. Data are show as mean $\pm$ Standard Error of the Mean (SEM)			
Statistics		Kruskal-Wallis test followed by Dunn's post-hoc analysis: * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle; # p < 0.05, ## p < 0.01 , ### p < 0.01 vs. COMPOUND 1; + p < 0.05, ++ p < 0.01, +++ p < 0.001 vs. VPA			
Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 30 mg/kg + vehicle	vehicle + VPA, 30 mg/kg	COMPOUND 1, 30 mg/kg + VPA, 30 mg/kg
Seizure stage		3.0 $\pm$ 0.0	1.8 $\pm$ 0.2 ***	2.9 $\pm$ 0.1 ##	2.0 $\pm$ 0.3 *
COMPOUND 1	Brain concentration - total (ng/g)		5228 $\pm$ 487		5104 $\pm$ 375
	Plasma concentration - total (ng/mL)		3087 $\pm$ 297		3148 $\pm$ 296
VPA	Brain concentration - total (ng/g)			1264 $\pm$ 399	1006 $\pm$ 117
	Plasma concentration - total (ng/mL)			23027 $\pm$ 3609	19933 $\pm$ 1648

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 30 mg/kg + vehicle	vehicle + VPA, 100 mg/kg	COMPOUND 1, 30 mg/kg + VPA, 100 mg/kg
Seizure stage		2.9 ± 0.1	1.7 ± 0.3	2.7 ± 0.2	0.1 ± 0.1 *** ; +++
COMPOUND 1	Brain concentration - total (ng/g)		5233 ± 343		5984 ± 336
	Plasma concentration - total (ng/mL)		4621 ± 556		2819 ± 256
VPA	Brain concentration - total (ng/g)			9278 ± 2535	5948 ± 946
	Plasma concentration - total (ng/mL)			68144 ± 6868	63400 ± 3213

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 30 mg/kg + vehicle	vehicle + VPA, 200 mg/kg	COMPOUND 1, 30 mg/kg + VPA, 200 mg/kg
Seizure stage		3.0 ± 0.0	1.2 ± 0.2 **	1.7 ± 0.4	0.0 ± 0.0 *** ; +
COMPOUND 1	Brain concentration - total (ng/g)		4387 ± 342		4994 ± 245
	Plasma concentration - total (ng/mL)		2832 ± 260		2108 ± 118
VPA	Brain concentration - total (ng/g)			24746 ± 3564	27012 ± 6539
	Plasma concentration - total (ng/mL)			108600 ± 9893	109520 ± 11385

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 10 mg/kg + vehicle	vehicle + VPA, 100 mg/kg	COMPOUND 1, 10 mg/kg + VPA, 100 mg/kg
Seizure stage		3.0 ± 0.0	3.0 ± 0.0	2.8 ± 0.2	2.1 ± 0.2 *** ; ### ; ++
COMPOUND 1	Brain concentration - total (ng/g)		1895 ± 75		2043 ± 178
	Plasma concentration - total (ng/mL)		1128 ± 98		710 ± 80
VPA	Brain concentration - total (ng/g)			10124 ± 2040	14628 ± 2906
	Plasma concentration - total (ng/mL)			53690 ± 4036	57270 ± 3762

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 10 mg/kg + vehicle	vehicle + VPA, 200 mg/kg	COMPOUND 1, 10 mg/kg + VPA, 200 mg/kg
Seizure stage		2.9 ± 0.1	2.7 ± 0.3	1.3 ± 0.3 ** ; #	0.8 ± 0.3 *** ; ###
COMPOUND 1	Brain concentration - total (ng/g)		1452 ± 104		1638 ± 52
	Plasma concentration - total (ng/mL)		2116 ± 175		1155 ± 73
VPA	Brain concentration - total (ng/g)			44222 ± 4088	34694 ± 4441
	Plasma concentration - total (ng/mL)			132578 ± 10721	122640 ± 11703

As can be seen from Table 1, in juvenile DBA/2J mice, combinations of COMPOUND 1
5 with valproic acid showed a synergistic antiepileptic effect on the induced audiogenic

seizure as compared to the effects observed when the drugs were given alone. For instance, the combination of a partially efficacious dose of COMPOUND 1 (30 mg/kg, seizure severity 2, corresponding to clonic seizure) with an inactive dose of valproic acid (100 mg/kg, seizure severity 3, corresponding to the tonic extension of the hind limbs) showed a synergistic antiepileptic effect and led to complete suppression of the audiogenic induced seizures. The synergistic effect is not the result of a pharmacokinetic interaction as plasma and brain concentrations of COMPOUND 1 and valproic acid were similar after administration of the compounds alone or in combination.

The results from the combination efficacy experiments using COMPOUND 1 and levetiracetam (LEV) are shown in Table 2.

Table 2: Efficacy of COMPOUND 1, LEV or its combination in audiogenic seizure-sensitive juvenile DBA/2J mice, a model of generalized convulsive seizures (n=9-10/group) with corresponding brain and plasma concentration.

Species		Juvenile male audiogenic seizure-sensitive DBA/2J mice (n = 9-10)			
Administration		Oral gavage, 5 mL/kg in 10 % PEG400 / 90 % MC0.5 %			
Assessment		Maximal seizure stage observed during exposure to auditory stimulus. Data are show as mean $\pm$ SEM			
Statistics		Kruskal-Wallis test followed by Dunn's post-hoc analysis: * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle; # p < 0.05, ## p < 0.01, ### p < 0.01 vs. COMPOUND 1; + p < 0.05, ++ p < 0.01, +++ p < 0.001 vs. LEV			
Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 30 mg/kg + vehicle	vehicle + LEV, 3 mg/kg	COMPOUND 1, 30 mg/kg + LEV, 3 mg/kg
Seizure stage		3.0 $\pm$ 0.0	1.9 $\pm$ 0.2 *	2.6 $\pm$ 0.3	0.6 $\pm$ 0.2 ***, +++
COMPOUND 1	Brain concentration - total (ng/g)		5042 $\pm$ 385		5956 $\pm$ 330
	Plasma concentration - total (ng/mL)		4453 $\pm$ 283		4534 $\pm$ 224
LEV	Brain concentration - total (ng/g)			675 $\pm$ 82	714 $\pm$ 59
	Plasma concentration - total (ng/mL)			1208 $\pm$ 76	1230 $\pm$ 64

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 30 mg/kg + vehicle	vehicle + LEV, 10 mg/kg	COMPOUND 1, 30 mg/kg + LEV, 10 mg/kg
Seizure stage		3.0 ± 0.0	1.6 ± 0.2 *	1.4 ± 0.3 *	0.3 ± 0.2 ***
COMPOUND 1	Brain concentration - total (ng/g)		4370 ± 334		5466 ± 533
	Plasma concentration - total (ng/mL)		4460 ± 322		4123 ± 315
LEV	Brain concentration - total (ng/g)			2307 ± 207	2149 ± 142
	Plasma concentration - total (ng/mL)			4007 ± 199	3877 ± 226

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 30 mg/kg + vehicle	vehicle + LEV, 50 mg/kg	COMPOUND 1, 30 mg/kg + LEV, 50 mg/kg
Seizure stage		3.0 ± 0.0	1.9 ± 0.3	0.5 ± 0.2 ***	0.1 ± 0.1 ***, #
COMPOUND 1	Brain concentration - total (ng/g)		4662 ± 275		4690 ± 399
	Plasma concentration - total (ng/mL)		4142 ± 178		3715 ± 351
LEV	Brain concentration - total (ng/g)			11318 ± 1440	13484 ± 1379
	Plasma concentration - total (ng/mL)			24156 ± 2669	26208 ± 2403

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 10 mg/kg + vehicle	vehicle + LEV, 1 mg/kg	COMPOUND 1, 10 mg/kg + LEV, 1 mg/kg
Seizure stage		3.0 ± 0.0	2.7 ± 0.2	3.0 ± 0.0	1.6 ± 0.4 **, #, ++
COMPOUND 1	Brain concentration - total (ng/g)		1435 ± 55		1934 ± 100
	Plasma concentration - total (ng/mL)		1318 ± 77		1498 ± 112
LEV	Brain concentration - total (ng/g)			224 ± 20	310 ± 34
	Plasma concentration - total (ng/mL)			541 ± 48	564 ± 42

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 10 mg/kg + vehicle	vehicle + LEV, 3 mg/kg	COMPOUND 1, 10 mg/kg + LEV, 3 mg/kg
Seizure stage		2.8 ± 0.2	2.9 ± 0.1	2.1 ± 0.4	1.1 ± 0.2 **, ##
COMPOUND 1	Brain concentration - total (ng/g)		2379 ± 164		2517 ± 190
	Plasma concentration - total (ng/mL)		1858 ± 116		1598 ± 111
LEV	Brain concentration - total (ng/g)			677 ± 70	787 ± 39
	Plasma concentration - total (ng/mL)			1170 ± 53	1250 ± 53

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 10 mg/kg + vehicle	vehicle + LEV, 10 mg/kg	COMPOUND 1, 10 mg/kg + LEV, 10 mg/kg
Seizure stage		2.3 ± 0.4	2.7 ± 0.2	1.7 ± 0.4	0.6 ± 0.2 *, ##
COMPOUND 1	Brain concentration - total (ng/g)		1965 ± 138		2026 ± 137
	Plasma concentration - total (ng/mL)		1894 ± 113		1586 ± 142
LEV	Brain concentration - total (ng/g)			2131 ± 267	2593 ± 169
	Plasma concentration - total (ng/mL)			4527 ± 473	5779 ± 232

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 10 mg/kg + vehicle	vehicle + LEV, 50 mg/kg	COMPOUND 1, 10 mg/kg + LEV, 50 mg/kg
Seizure stage		3.0 ± 0.0	2.7 ± 0.2	1.1 ± 0.3 **, #	0.5 ± 0.2 ***, ###
COMPOUND 1	Brain concentration - total (ng/g)		1743 ± 158		1811 ± 93
	Plasma concentration - total (ng/mL)		1785 ± 186		1715 ± 124
LEV	Brain concentration - total (ng/g)			11098 ± 886	12622 ± 549
	Plasma concentration - total (ng/mL)			26502 ± 2814	27010 ± 1349

As can be seen from Table 2, in juvenile DBA/2J mice, combinations of COMPOUND 1 with levetiracetam showed a synergistic antiepileptic effect on the induced audiogenic seizure as compared to the effects observed when the drugs were given alone. For instance, the combination of an inactive dose of COMPOUND 1 (10 mg/kg, seizure severity 3, corresponding to tonic extension of the hind limbs) and an inactive dose of levetiracetam (1 mg/kg, seizure severity 3, corresponding to the tonic extension of the hind limbs)

showed a synergistic antiepileptic effect and led to audiogenic induced seizures of reduced severity (1.6). The synergistic effect is not the result of a pharmacokinetic interaction as plasma and brain concentrations of COMPOUND 1 and LEV were similar after administration of the compounds alone or in combination.

- 5 The results from the combination efficacy experiments using COMPOUND 1 and lamotrigine (LTG) are shown in Table 3.

Table 3: Efficacy of COMPOUND 1, LTG or its combination in audiogenic seizure-sensitive juvenile DBA/2J mice, a model of generalized convulsive seizures (n=9-10/group) with corresponding brain and plasma concentration.

Species		Juvenile male audiogenic seizure-sensitive DBA/2J mice (n = 9-10)			
Administration		Oral gavage, 5 mL/kg in 10 % PEG400 / 90 % MC0.5 %			
Assessment		Maximal seizure stage observed during exposure to auditory stimulus. Data are show as mean $\pm$ SEM			
Statistics		Kruskal-Wallis test followed by Dunn's post-hoc analysis: * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle; # p < 0.05, ## p < 0.01 , ### p < 0.01 vs. COMPOUND 1; + p < 0.05, ++ p < 0.01, +++ p < 0.001 vs. LTG			
Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 30 mg/kg + vehicle	vehicle + LTG, 3 mg/kg	COMPOUND 1, 30 mg/kg + LTG, 3 mg/kg
Seizure stage		2.7 $\pm$ 0.2	2.0 $\pm$ 0.3	1.9 $\pm$ 0.2	0.9 $\pm$ 0.3 ***
COMPOUND 1	Brain concentration - total (ng/g)		4558 $\pm$ 317		5032 $\pm$ 238
	Plasma concentration - total (ng/mL)		4652 $\pm$ 243		4550 $\pm$ 293
LTG	Brain concentration - total (ng/g)			1491 $\pm$ 128	1367 $\pm$ 100
	Plasma concentration - total (ng/mL)			293 $\pm$ 27	284 $\pm$ 18

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 30 mg/kg + vehicle	vehicle + LTG, 10 mg/kg	COMPOUND 1, 30 mg/kg + LTG, 10 mg/kg
Seizure stage		3.0 ± 0.0	2.1 ± 0.2	1.4 ± 0.3 **	0.2 ± 0.2 ***, ##
COMPOUND 1	Brain concentration - total (ng/g)		4224 ± 261		4260 ± 350
	Plasma concentration - total (ng/mL)		4556 ± 285		3965 ± 372
LTG	Brain concentration - total (ng/g)			3262 ± 144	3658 ± 310
	Plasma concentration - total (ng/mL)			1203 ± 77	1332 ± 102

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 30 mg/kg + vehicle	vehicle + LTG, 30 mg/kg	COMPOUND 1, 30 mg/kg + LTG, 30 mg/kg
Seizure stage		3.0 ± 0.0	1.9 ± 0.3	0.2 ± 0.2 ***, #	0.0 ± 0.0 ***, ##
COMPOUND 1	Brain concentration - total (ng/g)		3618 ± 159		3286 ± 170
	Plasma concentration - total (ng/mL)		3968 ± 258		2915 ± 150
LTG	Brain concentration - total (ng/g)			8888 ± 248	8562 ± 853
	Plasma concentration - total (ng/mL)			3562 ± 165	2797 ± 475

Variable		Treatment group			
		vehicle + vehicle	COMPOUND 1, 10 mg/kg + vehicle	vehicle + LTG, 10 mg/kg	COMPOUND 1, 10 mg/kg + LTG, 10 mg/kg
Seizure stage		2.9 ± 0.1	2.8 ± 0.2	1.1 ± 0.3 ***, ###	1.4 ± 0.3 **, ##
COMPOUND 1	Brain concentration - total (ng/g)		1197 ± 80		1420 ± 165
	Plasma concentration - total (ng/mL)		1522 ± 109		1286 ± 140
LTG	Brain concentration - total (ng/g)			4054 ± 323	3687 ± 393
	Plasma concentration - total (ng/mL)			930 ± 77	859 ± 101

As can be seen from Table 3, in juvenile DBA/2J mice, combinations of COMPOUND 1 with with lamotrigine showed an improved antiepileptic effect on the induced audiogenic seizure as compared to the effects observed when the drugs were given alone. For instance, the combination of a partially efficacious dose of COMPOUND 1 (30 mg/kg, seizure severity 2, corresponding to clonic seizure) and a partially efficacious dose of lamotrigine (3 mg/kg, seizure severity 2, corresponding to clonic seizure) showed an increased antiepileptic effect and led to audiogenic induced seizures of reduced severity (1 corresponding to a wild running). The effect is not the result of a pharmacokinetic interaction as plasma and brain concentrations of COMPOUND 1 and lamotrigine were similar after administration of the compounds alone or in combination.

Pharmaceutical composition comprising COMPOUND 1:

A pharmaceutical composition comprising 10 mg of COMPOUND 1 was prepared as hard gelatine capsules (350 mg) using the following ingredients:

Ingredients	Role	mg / cps	%
COMPOUND 1	Active Ingredient	10.00	2.86
MCC (Avicel PH101)	Filler 1	207.38	59.25
Mannitol (Parteck M200)	Filler 2	88.87	25.39
PVP (Povidone, Kollidon 30)	Binder	17.50	5.00

cross-linked PVP (Crospovidone, Kollidon CL)	Disintegrant	17.50	5.00
Silica anhydrous (Aerosil 200)	Glidant	5.25	1.50
Magnesium Stearate (LUB Stab)	Lubricant	3.50	1.00
Total		350.00	100.00

Abbreviations:

cps: capsule; MCC: microcrystalline cellulose; PVP: polyvinylpyrrolidone

The hard gelatine capsules can be prepared according to the following process:

Step	Operation
1	Sieving of the inner phase (mixture of MCC, Mannitol, Povidone and Crospovidone) with a 800 µm sieve
2	Blending with a Turbula® shaker mixer (10 min at 32 rpm: Mixture A)
3	Combining of COMPOUND 1 with Mixture A (1 : 5 by weight) and mixing with a Turbula® shaker mixer (15 min at 32 rpm: Mixture B)
4	Sieving of Mixture B with a 800 µm sieve
5	Blending of Mixture B with a Turbula® shaker mixer (15 min at 32 rpm)
6	Transferring Mixture B to container with the remaining Mixture A (Mixture C)
7	Blending of Mixture C with a Turbula® shaker mixer (15 min at 32 rpm)
8	Compacting and granulating on a 800 µm sieve with a roller compactor (Mini-Pactor)
9	Blending with a Turbula® shaker mixer (10 min at 32 rpm)
10	Sieving of the anhydrous Silica (Glidant) with a 800 µm sieve and adding to Mixture C
11	Blending with a Turbula® shaker mixer (2 min at 32 rpm: Mixture D)
12	Sieving of the Magnesium Stearate (Lubricant) with a 800 µm sieve and adding to Mixture D
13	Blending with a Turbula® shaker mixer (2 min at 32 rpm: Mixture E)
14	Encapsulating with hard gelatine capsules Size 0

5 rpm: revolutions per minute

Claims:

1. Use of a pharmaceutical composition comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating epilepsy, tonic clonic seizures and/or absence seizures, wherein the pharmaceutical composition is to be administered with a pharmaceutical composition comprising a second active ingredient selected from the group consisting of (S)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof.
2. The use according to claim 1, wherein the second active ingredient is (S)-2-(2-oxopyrrolidin-1-yl)butanamide or a pharmaceutically acceptable salt thereof.
3. The use according to claim 1, wherein the second active ingredient is 2-propylpentanoic acid or a pharmaceutically acceptable salt thereof.
4. The use according to any one of claims 1 to 3, wherein the N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and the second active ingredient are comprised in a single pharmaceutical composition.
5. The use according to any one of claims 1 to 3, wherein the N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and the second active ingredient are comprised in separated pharmaceutical compositions.
6. The use according to any one of claims 1 to 5, in the manufacture of a medicament for treating epilepsy.
7. The use according to any one of claims 1 to 5 in the manufacture of a medicament for treating tonic clonic and/or absence seizures.
8. Use of a pharmaceutical composition comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically

acceptable salt thereof, and at least one therapeutically inert excipient, in the manufacture of a medicament for treating epilepsy, wherein the pharmaceutical composition is to be administered in combination with a second pharmaceutical composition containing, an active ingredient, (S)-2-(2-oxopyrrolidin-1-yl)butanamide and 2-propylpentanoic acid, or a
5 pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.